Page last updated: 2024-09-05

dabigatran and Thromboembolism, Venous

dabigatran has been researched along with Thromboembolism, Venous in 405 studies

Research

Studies (405)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	27 (6.67)	29.6817
2010's	316 (78.02)	24.3611
2020's	62 (15.31)	2.80

Authors

Authors	Studies
Chao, TF; Chen, MC; Chen, SW; Chu, PH; Chung, CM; Kuan, FC; Lin, YS; Lip, GYH; Wu, M; Wu, VC	1
Abuşka, D; Afacan, G; Ersan, E; Hosseinzadeh, M; Karcioglu, O; Ozkaya, B; Yeniocak, S; Yilmaz, S; Zengin, S	1
Gromov, K; Jensen, TB; Jimenez-Solem, E; Olesen, JB; Overgaard, S; Petersen, J; Schelde, AB	1
Albisetti, M; Brandão, LR; Male, C; Monagle, P; Young, G	1
Ammollo, CT; Colucci, M; Dellanoce, C; Dirienzo, L; Mancazzo, F; Paoletti, O; Testa, S; Vitulli, A	1
Chen, J; Chen, M; Fang, Z; Jiang, S; Lv, M; Qian, J; Wu, S; Xu, W; Zeng, Z; Zhang, J	1
Male, C	1
Cui, YM; Hu, K; Liu, ZY; Ma, LY; Mu, GY; Wang, Z; Wang, ZN; Xiang, Q; Xie, QF; Zhang, HX; Zhou, S	1
Brito, NC; de Brito, AFS; Ferreira Júnior, ABS; Ferreira, VL; Nita, ME; Riveros, BS; Tanaka, SKT	1
Ageno, W; Angiolillo, DJ; Barnes, GD; Bhatt, DL; Bikdeli, B; Connors, JM; Eikelboom, JW; Fanikos, J; Goldhaber, SZ; Jimenez, D; Kirtane, AJ; Krumholz, HM; Lip, GYH; Lippi, G; Lopes, RD; Mehran, R; Monreal, M; Parikh, SA; Piazza, G; Sadeghipour, P; Siegal, DM; Talasaz, AH; Weitz, JI; Zahedi Tajrishi, F	1
Emmens, W; Mitrovic, D; Naimi, A; van den Bemt, P; van der Mijle, A; van Roon, E; Veeger, N	1
Paik, J	1
Cao, S; He, T; Wu, X; Yu, B	1
Bi, G; Chen, J; Qin, X; Wu, F	1
Albisetti, M; Bomgaars, L; Brandão, LR; Chalmers, E; Felgenhauer, J; Halton, J; Luciani, M; Lvova, O; Mitchell, LG; Saracco, P; Simetzberger, M; Sun, Z; Tartakovsky, I	1
Arioli, D; Athanasiou, A; Ballestri, S; Capitelli, M; Cappi, C; Coluccio, V; Di Girolamo, M; Marietta, M; Marrazzo, A; Romagnoli, E	1
Chen, J; Chen, M; Fang, Z; Guan, C; Jiang, S; Lv, M; Qian, J; Wu, S; Xu, W; Zeng, Z; Zhang, J	1
Chai-Adisaksopha, C; Hantrakool, S; Hantrakun, N; Niprapan, P; Norasetthada, L; Piriyakhuntorn, P; Punnachet, T; Rattanathammethee, T; Rattarittamrong, E; Tantiworawit, A; Thiankhaw, K; Wongcharoen, W	1
Cober, MP; Fenn, NE; Hill, C; King, M; Mills, K; Omecene, NE; Pauley, JL; Sierra, CM; Smith, T	1
Dilokthornsakul, P; Nimworapan, M; Niyomsri, S; Wongcharoen, W	1
Hui, X; Li, J; Li, M; Ma, Y; Tian, J; Wang, Q; Wang, X; Xie, P; Yan, P; Yang, K; Yao, L	1
Ilc, S; Mavri, A	1
Arora, P; Ghanekar, S; Muehrcke, M; Russell, M	1
Gao, J; Miao, L; Shi, D; Shi, J; Song, L; Yu, H; Zhu, C	1
Akerman, M; Chin-Hon, J; Davenport, L; Hindenburg, A; Huang, J	1
Bang, SM; Jeong, HE; Park, S; Shin, JY; Yoon, D; You, SC	1
Buscarini, E; Coote, N; Droege, F; Dupuis-Girod, S; Fialla, AD; Geisthoff, U; Kjeldsen, A; Lenato, GM; Mager, HJ; Manfredi, G; Millar, CM; Pagella, F; Post, MC; Sabbà, C; Shovlin, CL; Suppressa, P; Sure, U; Torring, PM; Ugolini, S	1
Ayuk, P; Bingham, J; Kamali, F; Kampouraki, E; McDonald, L; Murphy, P; Sidgwick, F; Truemann, A	1
Albisetti, M; Bomgaars, L; Brandão, LR; Brueckmann, M; Chalmers, E; Gropper, S; Halton, J; Huang, F; Kreuzer, J; Kuhn, T; Luciani, M; Mitchell, LG; Nurmeev, I; Simetzberger, M; Sun, Z; Svirin, P; Tartakovsky, I; Zapletal, O	1
Buijs, JT; Najidh, S; Versteeg, HH	1
Albert, L; Bejjani, A; Coons, JC; Iasella, CJ	1
Branchford, BR; Goldenberg, NA	1
Choi, S; Hwang, KT; Jeong, SY; Koo, JW; Lee, JK; Park, KC	1
Auditeau, C; Blandinières, A; Gendron, N; Smadja, DM; Talbot, A	1
Ageno, W; Casella, IB; Chee, KH; Desch, M; Donado, E; Goldhaber, SZ; Reilly, PA; Schellong, S; Schulman, S; Singer, DE; Tang, W; Voccia, I	1
Branam, DL; Covert, K	1
Chaudhary, R; Garg, J; McBane, RD; Murad, MH; Pagali, S; Wysokinski, WE	1
As-Sultany, M; Donnachie, NJ; Finley, R; Highcock, AJ	1
Lobastov, KV; Schastlivtsev, IV	1
Ageno, W; Casella, IB; Chee, KH; Desch, M; Goldhaber, SZ; Schellong, S; Schulman, S; Singer, DE; Tang, W; Voccia, I; Zint, K	1
Corica, B; Proietti, M; Romiti, GF	1
Cui, Y; Jiang, J; Liu, Z; Mu, G; Wang, Z; Xiang, Q; Xie, Q; Zhang, H; Zhou, S	1
Davis, KA; Valanejad, SM	1
Allen, A; Patterson, ME; Rossier, C; Schaefer, M; Spoutz, P	1
Chan, N; Eikelboom, JW; Sobieraj-Teague, M	1
Kenet, G	1
Albisetti, M; Bomgaars, L; Brandão, LR; Brueckmann, M; Chalmers, E; Gorbatikov, K; Gropper, S; Halton, J; Huang, F; Kreuzer, J; Luciani, M; Mitchell, LG; Nurmeev, I; Reilly, P; Sharathkumar, A; Simetzberger, M; Sun, Z; Svirin, P; Tartakovsky, I	1
Brouwer, RW; Gerritsma-Bleeker, CL; Segers, M; van der Veen, L; van Hulst, M; van Raay, JJ; Veeger, NJ	1
Albisetti, M; Bergstrand, M; Bomgaars, L; Brandão, LR; Brueckmann, M; Chalmers, E; Gropper, S; Halton, J; Huang, F; Ibrahim, MMA; Joseph, D; Luciani, M; Mitchell, LG; Röshammar, D; Tartakovsky, I	1
Barnathan, E; Freedman, A; Larbi, L; Rao, G; Shoaibi, A; Truong, HQ; Wang, L; Weaver, J; Wildgoose, P; Wu, S; Yuan, Z	1
Chen, HY; Chou, KJ; Huang, CW; Lee, PT; Lin, PC; Ou, SH; Su, YC	1
Oh, HJ; Park, BJ; Ryu, KH; Yoon, BH	1
Alexandris-Souphis, T; Ali, MA; Barnes, GD; Decamillo, D; Errickson, J; Froehlich, JB; Haymart, B; Kaatz, S; Kline-Rogers, E; Kong, X; Kozlowski, JH; Krol, GD; Li, Y; Schaefer, JK; Shankar, SR; Sood, SL	1
Broniatowska, E; Papuga-Szela, E; Undas, A; Weronska, A	2
Dilcher, B; Hayward, I; Kline, J; Pagenhardt, J; Quedado, K	1
Eriksson, H; Ghanima, W; Kahn, SR; Morrison, D; Sandset, PM; Schulman, S; Wik, HS	1
Jiang, J; Li, W; Wang, M; Wang, S; Wang, X; Wu, T; Xie, J; Xue, E; Zhan, S; Zheng, H; Zhou, R	1
Ageno, W; Barco, S; Bouvaist, H; Brodmann, M; Couturaud, F; Cuccia, C; Dellas, C; Dimopoulos, K; Duerschmied, D; Empen, K; Faggiano, P; Ferrari, E; Galiè, N; Galvani, M; Ghuysen, A; Giannakoulas, G; Huisman, MV; Jiménez, D; Klok, FA; Konstantinides, SV; Kozak, M; Lang, IM; Lankeit, M; Mavromanoli, AC; Meneveau, N; Meyer, G; Münzel, T; Palazzini, M; Petris, AO; Piovaccari, G; Salvi, A; Schellong, S; Schmidt, KH; Schmidtmann, I; Toenges, G; Verschuren, F	1
Ageno, W; Casella, IB; Chee, KH; Goldhaber, SZ; Schellong, S; Schulman, S; Singer, DE; Tang, W; Voccia, I	1
Gkiatas, I; Korompilias, AV; Kostas-Agnantis, I; Papadopoulos, DV; Tsantes, AG; Ziara, P	1
Langer, F; Voigtlaender, M	1
Cifu, AS; Jain, A	1
Churilov, L; Hardidge, AJ; Suen, K; Westh, RN	1
Andreozzi, GM; Bignamini, AA; Kuca, P; Tomkowski, W	1
Imberti, D; Mastroiacovo, D	1
Casson, RJ; Chan, W; Sanders, P; Selva, D; Sun, MT; Wong, CX; Wood, MK	1
Davis, DO; Davis, KA	1
Douxfils, J; Gosselin, RC	1
Albisetti, M; Biss, B; Bomgaars, L; Brueckmann, M; Gropper, S; Halton, JML; Harper, R; Huang, F; Luciani, M; Maas, H; Mitchell, LG; Tartakovsky, I	1
Chu, XC; Gao, JH; Ning, B; Wang, LL; Zhao, CX	1
Ahuja, T; Cirrone, F; Green, D; Papadopoulos, J; Raco, V; Xiang, E	1
Basto, AN; Fewel, NP; Stock, EM; Ta, M; Vo, K	1
Beer, TM; Daughety, MM; DeLoughery, TG; Olson, SR; Shatzel, JJ	1
Ajzner, É; Bereczky, Z; Kappelmayer, J; Oláh, Z	1
Eriksson, H; Feuring, M; Fraessdorf, M; Goldhaber, SZ; Kakkar, A; Kreuzer, J; Schellong, S; Schüler, E; Schulman, S	1
Albisetti, M; Brandão, LR; Brueckmann, M; Chalmers, E; Gropper, S; Halton, JML; Harper, R; Huang, F; Maas, H; Mitchell, LG; Nurmeev, I; Picard, AC; Tartakovsky, I	1
Chan, NC; Weitz, JI	1
Hu, Y; Tang, L; Zhang, Z	1
Franco Moreno, AI; García Navarro, MJ; Martín Díaz, RM	1
Steuber, T	1
Boehlen, F; Fontana, P; Righini, M; Robert-Ebadi, H	1
Han, F; He, H; Ke, B; Li, X; Li, Y; Zeng, Y	1
Alonso, A; Chen, LY; Datta, YH; Lutsey, PL; MacLehose, RF; Norby, FL; Shah, S	1
Howard, LS	1
Ashley, J; Sood, MM	1
Koscielny, J; Rosenthal, C; von Heymann, C	1
Al-Samkari, H; Connors, JM	1
Banica, A; Benoit, B; Delisle, J; Fernandes, JC; Laflamme, GY; Malo, M; Nguyen, H; Ranger, P; Senay, A; Trottier, M	1
Bangdiwala, SI; Berwanger, O; Biccard, BM; Botto, F; Chaudhry, NK; Connolly, SJ; de Nadal, M; Devereaux, PJ; Duceppe, E; Eikelboom, JW; Erb, J; Franzosi, MG; Guyatt, G; Hoeft, A; Iglesias, PP; Kearon, C; Magloire, P; Mayosi, B; Meyhoff, CS; Neary, J; Pettit, S; Rahate, PV; Rao, M; Rao-Melacini, P; Rodseth, R; Sessler, DI; Sharma, M; Srinathan, SK; Szczeklik, W; Tandon, V; Villar, JC; Vincent, J; Xavier, D; Yusuf, S	1
Akl, EA; Barba, M; Hakoum, MB; Kahale, LA; Matar, CF; Schünemann, H; Sperati, F; Terrenato, I; Tsolakian, IG; Yosuico, VE	1
Ferreira, M; Feuring, M; Fraessdorf, M; Huisman, MV; Klok, FA	1
Azboy, I; Groff, H; Parvizi, J	1
Carrier, M; Khorana, AA; Lee, AYY; Meyer, G; Noble, S; O'Connell, C; Soff, G	1
Adam, TJ; Alonso, A; Lutsey, PL; MacLehose, RF; Roetker, NS; Zakai, NA	1
Brueckmann, M; Gropper, S; Halton, JML; Huang, F; Maas, H; Mitchell, LG; Stangier, J; Tartakovsky, I	1
Chabot, JA; Dwyer, FA; Jackson, TL; Kluger, MD; Morgan, JA; Rashid, MF; Schrope, BA	1
Al Yami, MS; Alfayez, OM; Alsheikh, R	1
Alonso, A; Chen, LY; Datta, YH; Lutsey, PL; MacLehose, RF; Norby, FL; Shah, S; Zakai, NA	1
Själander, A; Själander, S	1
Aisenberg, J; Elsaesser, A; Glund, S; Huisman, MV; Klok, FA; Lopes, RD; Pollack, CV; Reilly, P; Van der Wall, SJ; van Ryn, J	1
Ageno, W; Agnelli, G; Chan, NC; De Caterina, R; Diener, HC; Hylek, E; Lip, GYH; Raskob, GE; Siegal, DM; Verheugt, FWA; Weitz, JI	1
Kopytek, M; Natorska, J; Undas, A; Ząbczyk, M	1
Oo, TH; Rojas-Hernandez, CM	1
Buijs, JT; Crooijmans, JJ; Kroone, C; Laghmani, EH; Le Dévédec, SE; Tieken, C; van den Akker, RFP; van der Molen, KM; van der Pluijm, G; Versteeg, HH; Vletter, EM	1
Nowak, K; Pac, A; Stepien, K; Undas, A; Zalewski, J	1
Fong, A; Mathew, J; Povlow, MR	1
Imberti, D; Mastroiacovo, D; Pomero, F	1
Chen, H; Deng, Y; Li, S; Tong, Y; Zou, L	1
Connors, JM	1
Baanstra, D; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Kvamme, AM; Mismetti, P; Schellong, S; Schulman, S	1
Ageno, W; Bozzato, S; Donadini, MP; Riva, N	1
Akwaa, F; Spyropoulos, AC	2
Guijarro Merino, R; Villalobos Sánchez, A	1
Marchena Yglesias, PJ	1
Castillo, J; de Andrés, J; Ferrandis, R; Gomar, C; Gómez-Luque, A; Hidalgo, F; Llau, JV; Torres, LM	1
Camarero, MO; Castaño, MP; Milla, SL; Piñero-Saavedra, M	1
Dalla Valle, F; Pesavento, R; Piovella, C; Prandoni, P; Tormene, D	1
Kwok, CS; Loke, YK; Pradhan, S; Yeong, JK	1
Calvo Romero, JM; Lima Rodríguez, EM	1
Adler, D; Beeton, A; Büller, H; de Jong, PR; Haas, S; Hsu, HC; Jacobson, BF; Louw, S; Mer, M; Rowji, P; Schapkaitz, E; Wessels, P	1
Spyropoulos, AC; Turpie, AG	1
Gallego, P; Lip, GY; Roldan, V	1
Einecke, D	1
Bates, P; Culpan, P; El-Daly, I; Reidy, J	1
Páramo, JA	1
Wanat, MA	1
den Exter, PL; Huisman, MV; Kooiman, J; van der Hulle, T	1
Agnelli, G; Becattini, C; Franco, L	1
Eriksson, BI; Quinlan, DJ	1
Cohen, AA; Rider, T	1
Barco, S; Cheung, YW; Coppens, M; Eikelboom, JW	1
Kansal, AR; Pokora, T; Sorensen, SV; Zheng, Y	1
Brosa, M; Diamantopoulos, A; Folkerts, K; Imberti, D; Monreal, M	1
Cameron, C; Carrier, M; Castellucci, LA; Clifford, T; Coyle, D; Gandara, E; Le Gal, G; Rodger, MA; Wells, G; Wells, PS	1
Adam, SS; Lachiewicz, PF; McDuffie, JR; Ortel, TL; Williams, JW	1
Brueckmann, M; Connolly, SJ; Eikelboom, JW; Ezekowitz, MD; Fraessdorf, M; Hwang, HG; Majeed, A; Schulman, S; Wallentin, L; Yusuf, S	1
Atar, D; Ghanima, W; Sandset, PM	1
Barbar, S; Milan, M; Pesavento, R; Prandoni, P; Vedovetto, V	1
Clemens, A; Fraessdorf, M; Friedman, J	1
Cove, CL; Hylek, EM	1
Aldin, ES; Greenberg, C; Rachidi, S; Sachs, B; Streiff, M; Zeidan, AM	1
Dütsch, M; Klauser, W	1
Laffan, M; Shapiro, S	1
Dekkers, OM; den Exter, PL; Huisman, MV; Klok, FA; Kooiman, J; van der Hulle, T	1
Bounameaux, H; Verhamme, P	1
Christiansen, AV; Eriksson, H; Friedman, J; Goldhaber, SZ; Kakkar, AK; Kearon, C; Le Maulf, F; Mismetti, P; Peter, N; Schellong, S; Schulman, S	1
Best, AJ; Bloch, BV; Patel, V	1
Carter, A; Corbett, S; George, M; Sarda, P	1
Schulman, S	3
Basile, E; Di Biase, L; Giglio, AF; Natale, A; Santangeli, P; Trotta, F	1
Bounameaux, H; Fontana, P; Goldhaber, SZ	1
Brown, R; Gallego, P; Lip, GY	1
Antoniazzi, S; Berdaï, D; Clementi, E; Conti, V; Salvo, F	1
Thachil, J	1
Brieger, D	1
Cohen, AT; Imfeld, S; Rider, T	1
Prandoni, P; Taher, A; Temraz, S	1
Beer, JH; Holy, EW	1
Avendaño-Solá, C; Gómez-Outes, A; Terleira-Fernández, AI; Vargas-Castrillón, E	1
Bruyère, O; Buckinx, F; Dogné, JM; Douxfils, J; Hainaut, P; Minet, V; Mullier, F; Rabenda, V; Reginster, JY	1
Gross, PL; Weitz, JI; Yeh, CH	1
Lévy, S	1
Kakkos, SK; Kirkilesis, GI; Tsolakis, IA	1
Büller, HR; Coppens, M; Middeldorp, S; Schulman, S; van Es, N	1
Chatterjee, S; Ghosh, J; Giri, JS; Mukherjee, D; Sardar, P	1
Akl, EA; Barba, M; Kahale, L; Labedi, N; Muti, P; Neumann, I; Schünemann, H; Sperati, F; Terrenato, I	1
Gómez-Outes, A; Lecumberri, R; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E	1
Rodgers, GM; Win, K	1
Alotaibi, G; Alsaleh, K; Mcmurtry, MS; Wu, C	1
Amin, A; Graham, J; Jing, Y; Lin, J; Lingohr-Smith, M; Trocio, J	1
Garg, P; Morris, P; Morris, PD; Saraf, K; Sheridan, P; Storey, R	1
Donovan, JL; Kanaan, AO; Rollins, BM; Silva, MA	1
Binder, K; Domanovits, H; Eichinger, S; Függer, R; Gollackner, B; Hiesmayr, JM; Huber, K; Kyrle, PA; Lang, W; Perger, P; Quehenberger, P; Roithinger, FX; Schmaldienst, S; Weltermann, A	1
Hunt, BJ; Sciascia, S	1
Giugliano, RP; Plitt, A	1
Greig, SL; McKeage, K	1
Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S	1
Dobesh, PP; Fanikos, J	1
Ageno, W; Beyer-Westendorf, J	1
Berghold, A; Kemperdick, B; Mergenthal, K; Petersen, JJ; Rauck, S; Roehl, I; Schulz-Rothe, S; Siebenhofer, A; Ulrich, LR	1
Cui, J; Li, Z; Liu, C; Wu, B	1
Jackson, LR; Okeagu, E; Peterson, ED; Thomas, K	1
Baber, U; Mastoris, I; Mehran, R	1
Bell, AD; Douketis, J; Eikelboom, J; Liew, A	2
Hajhosseiny, R; Lip, GY; Sabir, I	1
Belikov, LN; Savchuk, OF; Sukovatykh, BS; Sukovatykh, MB	1
Amin, A; Bruno, A; Lin, J; Lingohr-Smith, M; Trocio, J	1
Arepally, GM; Ortel, TL	1
Harel, Z; Perl, J; Sood, MM	1
Bacchus, F; Schulman, S	1
Eriksson, H; Feuring, M; Goldhaber, SZ; Hantel, S; Kakkar, AK; Kearon, C; Kreuzer, J; Schellong, S; Schulman, S	1
Bonfanti, C; Franchini, M; Lippi, G	1
Altimari, V; Bacchin, MR; Bonarelli, S; Facchini, F; Feoli, MA; Frugiuele, I	1
Agnelli, G; Prandoni, P; Verso, M	1
Bass, AR	1
Dias, JD; Doorneweerd, DD; Norem, K; Omert, LA; Popovsky, MA; Thurer, RL	1
Fanola, CL	1
Mateo Arranz, J; Millón Caño, JA; Souto Andrés, JC; Vilalta Setó, N	1
Lip, GY; Proietti, M	1
Ge, D; Morrill, AM; Willett, KC	1
Schellong, SM	1
Butera, JN; Connell, NT	1
Alexander, GC; Barnes, GD; Goldberger, ZD; Lucas, E	1
Law, EH; Leung, TS	1
Bolton-Maggs, PH; Shearer, MJ; Thachil, J; Walsh, V	1
Bächli, E; Walti, C	1
Drambarean, B; Hellenbart, E; Lee, J; Nutescu, EA	1
Aryal, MR; Donato, AA; Ghimire, S; Giri, S; Jehangir, A; Karmacharya, P; Pathak, R; Poudel, DR; Rettew, A; Shaikh, B	1
Jugrin, AV; Lamotte, M; Sunderland, T; Urbich, M; Ustyugova, A	1
Fosbøl, E; Gislason, G; Jensen, P; Jensen, T; Koeber, L; Olesen, J; Thorsberger, M; Torp-Pedersen, C; Wahlsten, L; Weeke, P	1
De Francesco, M; Hösel, V; Jugrin, AV; Lamotte, M; Sunderland, T; Ustyugova, A	1
Eriksson, H; Feuring, M; Friedman, J; Goldhaber, SZ; Hantel, S; Kakkar, A; Kearon, C; Kreuzer, J; Majeed, A; Schellong, S; Schulman, S	1
Goldenberg, NA; Kittelson, JM; Massicotte, MP; Takemoto, CM; Yee, DL	1
Gross, PL; Ni, R; Saldanha, LJ; Shaya, SA; Vaezzadeh, N; Zhou, J	1
Ageno, W; Bauersachs, R; Couturaud, F; Décousus, H; Mismetti, P	1
Budykina, TS; Khorikova, EN; Mikhailova, IS; Mravyan, SR; Popov, VV; Pronina, VP; Shuginin, IO; Stepanova, EA	1
Gonzalez, MG; Levy, PD; Peacock, WF; Than, M	1
Kesteven, P; McCaslin, JE; Robertson, L	1
Smith, LL	1
Batson, S; Bird, A; Cohen, AT; Hamilton, M; Liu, X; Mitchell, SA; Phatak, H; Tushabe, D	1
Rostagno, C	1
Besselaar, A; Boonen, K; Hendriks, JG; Jonkers, F; Schellings, MW; Schmitz, EM; van de Kerkhof, D; van den Heuvel, DJ	1
Dobesh, PP; Finks, SW; Trujillo, TC	1
Browne, C; Cohen, AT; Hamilton, M; Lanitis, T; Leipold, R; Quon, P; Rublee, D	1
Boehlen, F; Bounameaux, H; Fontana, P; Righini, M; Robert-Ebadi, H	1
Pan, EY; Sobieraj, DM	1
Loffredo, L; Perri, L; Violi, F	1
Majeed, A; Schulman, S; Shrum, J	1
Agnelli, G; Becattini, C	1
Bansal, M; Ren, CL	1
Babhulkar, S; Clemens, A; Dadi, A; Iyer, R; Kamath, S; Malhotra, R; Mody, B; Mutha, S; Reddy, G; Sanjib, KB; Shah, V; Shetty, N; Tapasvi, S; Wadhwa, M	1
Feuring, M; van Ryn, J	1
Greinacher, A; Vanassche, T; Verhamme, P	1
Alves Júnior, JL; Fernandes, CJ; Gavilanes, F; Morinaga, LK; Prada, LF; Souza, R	1
Brueckmann, M; Clemens, A; Feuring, M; Frostick, SP; Gullberg, J; Kleine, E; Rosencher, N; Samama, CM	1
Boey, JP; Gallus, A	1
Godier, A; Martin, AC; Rosencher, N; Susen, S	1
Kaminskas, E; Reiffel, JA; Reilly, P; Sager, P; Sarich, T; Seltzer, J; Weitz, JI	1
Barra, ME; Connors, JM; Fanikos, J; Goldhaber, SZ; Piazza, G; Sylvester, KW	1
Amiral, J; Eriksson, BI; Feuring, M; Haertter, S; Mikuska, Z; Nehmiz, G; Stangier, J; Weitz, JI	1
Belletrutti, M; Cronin, L; Haertter, S; Halton, JM; Lehr, T; Lobmeyer, MT; Mitchell, LG	1
Ageno, W; Eikelboom, J; Lip, GY	1
Eriksson, H; Feuring, M; Fraessdorf, M; Goldhaber, SZ; Kakkar, A; Kreuzer, J; Schellong, S; Schulman, S	1
Clemens, A; Hösel, V; Klok, FA; Konstantinides, SV; Lankeit, M; Schulman, S; Tilke, C; Yollo, WD	1
Batson, S; Bird, A; Cohen, AT; Hamilton, M; Horblyuk, R; Li, S; Mitchell, SA	1
Benedetti, R; Fenoglio, L; Imberti, D; Pomero, F	1
Jaffer, IH; Weitz, JI	1
Hansrani, V; Khanbhai, M; McCollum, C	1
Davies, AH; Lim, CS; Ravikumar, R	1
Chaiyakunapruk, N; Chongmelaxme, B; Kotirum, S	1
Koyfman, A; Long, B	1
de Jong, LA; Dvortsin, EP; Kappelhoff, BS; Postma, MJ; Stevanović, J; Voorhaar, M	1
Butala, NM; Kartoun, U; Kennedy, KF; Mahmood, S; Secemsky, EA; Shaw, SY; Wasfy, JH; Yeh, RW	1
Eriksson, H; Feuring, M; Fraessdorf, M; Goldhaber, SZ; Kakkar, A; Kreuzer, J; Schellong, S; Schueler, E; Schulman, S	1
Gage, BF; Ganti, BR; Lee, ED; Lin, H; Nunley, RM; Venker, BT	1
Ageno, W; Casella, IB; Desch, M; Goldhaber, SZ; Han, CK; Kimura, K; Raskob, GE; Schellong, S; Schulman, S; Singer, DE; Tang, W	1
Goralczyk, T; Undas, A	1
Chung, MK; Cigarroa, JE; Collins, SP; Diaz-Sandoval, LJ; Diercks, D; Jung, HS; Piccini, JP; Raval, AN; Washam, JB; Welch, BG; Zazulia, AR	1
Ageno, W; Becattini, C; D'Angelo, A; Davì, G; De Cristofaro, R; Dentali, F; Di Minno, G; Falanga, A; Gussoni, G; Masotti, L; Palareti, G; Pignatelli, P; Prisco, D; Santi, RM; Santilli, F; Silingardi, M; Tufano, A; Violi, F	1
Bhagirath, VC; Eikelboom, JW; Monagle, S; Ng, KH	1
Weitz, JI	2
Eriksson, H; Feuring, M; Goldhaber, SZ; Hantel, S; Kakkar, AJ; Kreuzer, J; Schellong, S; Schueler, E; Schulman, S	1
EncisoSilva, J; Greenberg, B; Schlueter, M; Thomas, I	1
Carrier, M; de Wit, C; Le Gal, G; Shaw, J	1
Caprini, JA; Clements, ML; Comp, PC; Davidson, BL; Francis, CW; Friedman, RJ; Ginsberg, JS; Hantel, S; Huo, MH; Lieberman, JR; Muntz, JE; Raskob, GE; Schnee, JM	1
Eriksson, BI; Kirkpatrick, P; Smith, H; Yasothan, U	1
Turpie, AG	1
Spyropoulos, AC	1
Ferrandis, R; Llau, JV; López Forte, C; Sapena, ML	1
Eikelboom, JE; Weitz, JI	1
Caprini, JA; Eriksson, BI; Plumb, JM; Roskell, NS; Wolowacz, SE	1
Farley, TM; Lewis, D; Macaulay, TE	1
Beard, SM; Brenkel, IJ; Dolan, G; Maciver, F; Plumb, JM; Robinson, PA; Roskell, NS; Wolowacz, SE	1
Lassen, MR; Laux, V	1
Harenberg, J; Nitschmann, S	1
Kamphuisen, PW; Leebeek, FW	1
Arya, R; Roberts, LN	1
Crowther, MA; Lepic, K	1
Borris, LC	1
Barry, M; McCullagh, L; Tilson, L; Walsh, C	1
Carroll, C; Holmes, M; Papaioannou, D	2
Fuijita, S; Fuji, T; Sato, T; Ujihira, T	1
Wittkowsky, AK	1
Baanstra, D; Eriksson, H; Goldhaber, SZ; Kakkar, AK; Kearon, C; Mismetti, P; Schellong, S; Schnee, J; Schulman, S	1
Brenkel, IJ; Clemens, A; Dolan, G; Noack, H; Plumb, JM; Robinson, PA; Roskell, NS; Wolowacz, SE	1
Conard, J; Horellou, MH; Samama, MM	1
Ferrer, E	1
Verma, AK	1
Caglayan, E; Er, F; Erdmann, E; Gassanov, N	1
Argyle, RA; Lomas, O; Prendergast, BD	1
Lackner, KJ; Peetz, D	1
Teachey, DT	1
Prandoni, P; Taher, A	1
Clemens, A; Feuring, M; Haertter, S; Liesenfeld, KH; Stangier, J; van Ryn, J; Wienen, W	1
Malaga, G; Malasquez, G; Salazar, CA	1
Kolundzic, R; Trkulja, V	1
Bauer, KA	1
Eikelboom, JW; Hirsh, J; Karthikeyan, G	1
Caprini, JA; Clemens, A; Dahl, OE; Eriksson, BI; Francis, CW; Friedman, RJ; Hantel, S; Kurth, AA; Rosencher, N; Schnee, JM	1
Liakishev, AA	1
Brant, R; Hull, RD; Liang, J	1
Shakib, S; Tadros, R	1
Cohen, AF; Dubois, EA	1
Daskalopoulos, ME; Karangelis, D; Tagarakis, GI; Tsilimingas, NB	1
Clemens, A; Monz, BU; Plumb, JM	1
Crowther, M; Lepic, K	1
Lam, YY; Ma, TK; Yan, BP	1
Dahl, OE; Huisman, MV; Quinlan, DJ; Schulman, S	1
Giannoudis, PV; Harwood, PJ; Karadimas, EJ; Nikolaou, VS; Tan, HB	1
Morris, TA	1
Michota, F	1
Lancellotti, P; Scheen, AJ	1
Oliver, M	1
Savchuk, OF; Sukovatykh, BS	1
Kwok, CS; Loke, YK	1
Dahl, OE; Eriksson, BI; Friedman, RJ; Hantel, S; Hermansson, K; Huo, MH; Kurth, AA; Schnee, JM	1
Ansell, JE; Lee, CJ	1
Eikelboom, JW; Weitz, JI	1
Wolowacz, SE	1
Ageno, W; Prandoni, P	1
Diamantopoulos, A; Lees, M; Lereun, C; Rasul, F; Sengupta, N; Wells, P	1
Samama, CM	1
Ageno, W; Streif, W	1
Braunwald, E; Steffel, J	1
Douketis, JD	1
Guay, DR	1
Gums, JG	1
Cerbone, AM; Coppola, A; Franchini, M; Ruosi, C; Tufano, A	1
Eikelboom, JW; Hankey, GJ	1
Fisher, WD	1
Nutescu, E	1
Friedman, RJ	2
Majeed, A; Schulman, S	1
Ajzenberg, N; Dumont, B; Faille, D	1
Fareed, J; Hull, R; Welzel, D	1
Keltai, K; Keltai, M	1
Fadda, V; Maratea, D; Messori, A; Trippoli, S	1
Blommel, AL; Blommel, ML	1
Asmis, LM	1
Büller, HR; Eerenberg, ES; Kamphuisen, PW; Sijpkens, MK; van Es, J	1
Pendleton, RC; Rodgers, GM; Smock, KJ; Wilcox, R	1
Beer, JH	1
Augoustides, JG	1
Almozlino, A; Arpino, PA; Atay, JK; Berliner, N; Block, CC; Connors, JM; Fischer, MA; Giugliano, RP; Hutter, AM; Kuter, D; Piazza, G; Reddy, P; Selbovitz, LG; Sherwood, GK; Weitzman, J	1
Clemens, A; Dahl, OE; Eriksson, BI; Kurth, AA; Noack, H; Rosencher, N	1
Deloughery, TG; Liem, TK	1
Albaladejo, P; Rosencher, N	1
Migliaccio-Walle, K; Rublee, D; Simon, TA	1
Dahl, OE	1
Mahan, C; Spyropoulos, AC	1
Barrellier, MT; Dutheil, JJ; Gouzy, S; Lebel, B; Malherbe, M; Parienti, JJ; Vielpeau, C	1
Cohen, A; Drost, P; Marchant, N; Mitchell, S; Orme, M; Rublee, D; Simon, TA; Sutton, A	1
Khemasuwan, D; Suramaethakul, N	1
Espada, NG; González, TC; Merino, RG; Nieto, JA	1
Palareti, G; Tripodi, A	1
Garza, R; Huo, MH	1
Cohen, AT	1
Duh, PD; Leuckx, PS; Warnez, PM	1
Brouwers, JR; Kappelhoff, BS; Postma, MJ; van Hulst, M	1
Burness, CB; McKeage, K	1
Barry, M; McCullagh, L; Walsh, C	1
Gómez-Outes, A; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E	1
Pollack, CV	1
Barry, M; McCullagh, L	1
Clemens, A; Dahl, OE; Eriksson, BI; Feuring, M; Friedman, RJ; Hantel, S; Huo, M; Noack, H	1
Clemens, A; Dahl, OE; Eriksson, BI; Hantel, S; Kurth, AA; Rosencher, N	1
Dahl, OE; Harenberg, J; Marder, VJ; Marx, S; Schulze, A; Wehling, M; Weiss, C	1
Haas, S; Kreutz, R; Llau, J; Norrving, B; Turpie, AG	1
McBane, RD; Tafur, A; Wysokinski, WE	1
Aspoeck, G; Goebel, G; Griesmacher, A; Halbmayer, WM; Haushofer, AC; Loacker, L; Quehenberger, P; Schnapka-Koepf, M; Tomasits, J; Weigel, G	1
Aalbers, J	1
Blanco-Molina, A	1
García Alegría, J	1
Suárez Ortega, S	1
Kaatz, S; Mahan, CE	1
Lazo-Langner, A; Sun, D	1
Boehlen, F; de Moerloose, P	1
Martin, EN; Money, SR; Shamoun, FE	1
Gulseth, M; Hellwig, T	1
Eraso, LH; Merli, GJ; Perez, A	1
Jackiewicz, A; Krzemiński, M; Mrozik, D	1
Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C	1
Debue, JM; Guinet, C; Le Flem, L; Ninin, E; Samama, MM	1
Graff, J; Harder, S	1
Garcia, DA; Rojas-Hernandez, CM	1
Ma, Q	1
Martins, HS; Scalabrini-Neto, A; Velasco, IT	1
Gross, PL; Weitz, JI	1
Harenberg, J; Wehling, M	1
Brotman, DJ; Jaffer, AK	1
Klapper, U; Messer, I; Neumann, K; Röleke, D; Seidel, U; Werner, A; Wilke, T	1

Reviews

216 review(s) available for dabigatran and Thromboembolism, Venous

Article	Year
An Update of the Efficacy and Comparative Characteristics of Direct (New) Oral Anticoagulants (DOACs). Cardiovascular & hematological agents in medicinal chemistry, 2022, Volume: 20, Issue:2 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Venous Thromboembolism	2022
Editor's Choice - Severe Bleeding Risks of Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism: A Network Meta-Analysis of Randomised Controlled Trials. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2022, Volume: 63, Issue:3 Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Network Meta-Analysis; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism	2022
Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies. BMC cardiovascular disorders, 2022, 03-14, Volume: 22, Issue:1 Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Rivaroxaban; Venous Thromboembolism	2022
Thromboprophylaxis of Patients Submitted to Total Hip and Knee Arthroplasty: A Cost-Effectiveness Assessment From the Perspective of the Brazilian National Health System. Value in health regional issues, 2022, Volume: 31 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Brazil; Cost-Benefit Analysis; Dabigatran; Enoxaparin; Humans; Rivaroxaban; Venous Thromboembolism	2022
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review. JAMA cardiology, 2022, 07-01, Volume: 7, Issue:7 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Rivaroxaban; Stroke; Venous Thromboembolism	2022
Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism. Paediatric drugs, 2022, Volume: 24, Issue:4 Topics: Administration, Oral; Anticoagulants; Child; Dabigatran; Hemorrhage; Humans; Venous Thromboembolism	2022
Comparing the efficacy and safety of direct oral anticoagulants versus Vitamin K antagonists in patients with antiphospholipid syndrome: a systematic review and meta-analysis. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2022, Oct-01, Volume: 33, Issue:7 Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Dabigatran; Fibrinolytic Agents; Hemorrhage; Humans; Rivaroxaban; Thrombosis; Venous Thromboembolism; Vitamin K	2022
Direct oral anticoagulants versus standard anticoagulation in children treated for acute venous thromboembolism. Pediatric research, 2023, Volume: 93, Issue:6 Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Child; Dabigatran; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism	2023
Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review. Advances in therapy, 2023, Volume: 40, Issue:1 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Dabigatran; Gastrointestinal Hemorrhage; Humans; Rivaroxaban; Stroke; Venous Thromboembolism	2023
Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022, Volume: 30, Issue:12 Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Network Meta-Analysis; Rivaroxaban; Venous Thromboembolism; Warfarin	2022
Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis. International journal of environmental research and public health, 2023, 02-11, Volume: 20, Issue:4 Topics: Anticoagulants; Cost-Benefit Analysis; Dabigatran; Humans; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Thailand; Venous Thromboembolism; Warfarin	2023
Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis. The Cochrane database of systematic reviews, 2023, 04-14, Volume: 4 Topics: Anticoagulants; Antithrombins; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Neoplasm Recurrence, Local; Pulmonary Embolism; Rivaroxaban; Venous Thromboembolism; Venous Thrombosis	2023
Studies on Atrial Fibrillation and Venous Thromboembolism in the Past 20 Years: A Bibliometric Analysis Via CiteSpace and VOSviewer. Journal of the American Heart Association, 2023, 09-05, Volume: 12, Issue:17 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Venous Thromboembolism; Warfarin	2023
A systematic review on the effects of direct oral anticoagulants on cancer growth and metastasis in animal models. Thrombosis research, 2020, Volume: 187 Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Dabigatran; Humans; Mice; Models, Animal; Neoplasms; Pyrazoles; Pyridones; Rats; Rivaroxaban; Venous Thromboembolism	2020
[The role of direct oral anticoagulants in the management of cancer-associated thrombosis in 2020]. Bulletin du cancer, 2020, Volume: 107, Issue:5 Topics: Anticoagulants; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasm Proteins; Neoplasms; Pyrazoles; Pyridines; Pyridones; Recurrence; Rivaroxaban; Secondary Prevention; Thiazoles; Thrombosis; Venous Thromboembolism	2020
Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2020, 05-19, Volume: 77, Issue:11 Topics: Anticoagulants; Body Weight; Dabigatran; Drug Dosage Calculations; Factor Xa Inhibitors; Humans; Obesity; Overweight; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism	2020
DOACs Versus VKAs in Older Adults Treated for Acute Venous Thromboembolism: Systematic Review and Meta-Analysis. Journal of the American Geriatrics Society, 2020, Volume: 68, Issue:9 Topics: Administration, Oral; Aged; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism; Vitamin K	2020
[Peculiarities of the treatment of venous thromboembolism with direct oral anticoagulants in challenging patients: senile age, renal failure, fragility]. Khirurgiia, 2020, Issue:7 Topics: Administration, Oral; Age Factors; Aged; Antithrombins; Dabigatran; Frail Elderly; Humans; Pyrazoles; Pyridones; Renal Insufficiency; Rivaroxaban; Venous Thromboembolism	2020
A comprehensive appraisal of dabigatran etexilate clinical evidence and applications: a 10-year-long story. Future cardiology, 2021, Volume: 17, Issue:2 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Stroke; Venous Thromboembolism	2021
Different Coagulation Indicators in Predicting Clinical Outcomes for Patients With Direct Oral Anticoagulants: A Systematic Review and Meta-analysis. Clinical therapeutics, 2020, Volume: 42, Issue:10 Topics: Administration, Oral; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Prothrombin Time; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism	2020
Direct Oral Anticoagulants in Select Patients With Hypercoagulable Disorders. The Annals of pharmacotherapy, 2021, Volume: 55, Issue:7 Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Rivaroxaban; Thrombophilia; Venous Thromboembolism	2021
Direct oral anticoagulants: evidence and unresolved issues. Lancet (London, England), 2020, 11-28, Volume: 396, Issue:10264 Topics: Administration, Oral; Anticoagulants; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism	2020
Comparative Risk Assessment of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants: A Network Study Across Four Observational Databases in the USA. Drug safety, 2021, Volume: 44, Issue:4 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Observational Studies as Topic; Pyridones; Risk Assessment; Rivaroxaban; Uterine Hemorrhage; Venous Thromboembolism; Warfarin	2021
Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis. Clinical drug investigation, 2021, Volume: 41, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Stroke; Venous Thromboembolism; Warfarin	2021
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis. Medicine, 2021, Mar-19, Volume: 100, Issue:11 Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Network Meta-Analysis; Observational Studies as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin	2021
Wound complications and bleeding with new oral anticoagulants in patients undergoing total joint arthroplasty: A systematic review and meta-analysis of randomized controlled trials. British journal of clinical pharmacology, 2022, Volume: 88, Issue:2 Topics: Administration, Oral; Anticoagulants; Arthroplasty; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism	2022
The role of new oral anticoagulants in orthopaedics: an update of recent evidence. European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2017, Volume: 27, Issue:5 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Tests; Dabigatran; Factor Xa; Hemorrhage; Humans; Orthopedic Procedures; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism	2017
Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. What do we know so far? Hamostaseologie, 2017, Oct-27, Volume: 37, Issue:4 Topics: Acute Disease; Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Guideline Adherence; Heparin, Low-Molecular-Weight; Humans; Long-Term Care; Neoplasms; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism	2017
Low-Molecular-Weight Heparin and the Relative Risk of Surgical Site Bleeding Complications: Results of a Systematic Review and Meta-Analysis of Randomized Controlled Trials of Venous Thromboprophylaxis in Patients After Total Joint Arthroplasty. The Journal of arthroplasty, 2017, Volume: 32, Issue:9 Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Knee; Aspirin; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Incidence; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Treatment Outcome; Venous Thromboembolism; Warfarin	2017
Risk of Intraocular Bleeding With Novel Oral Anticoagulants Compared With Warfarin: A Systematic Review and Meta-analysis. JAMA ophthalmology, 2017, 08-01, Volume: 135, Issue:8 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Eye Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin	2017
Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis. Medicine, 2017, Volume: 96, Issue:40 Topics: Anticoagulants; Arthroplasty; Azetidines; Benzylamines; Dabigatran; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Network Meta-Analysis; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Treatment Outcome; Venous Thromboembolism; Warfarin	2017
Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide. Journal of oncology practice, 2017, Volume: 13, Issue:11 Topics: Androgen Receptor Antagonists; Anticoagulants; Atrial Fibrillation; Benzamides; Dabigatran; Drug Interactions; Embolism; Heart Valve Prosthesis; Heparin, Low-Molecular-Weight; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin	2017
[Laboratory aspects of novel oral anticoagulant treatment]. Orvosi hetilap, 2017, Volume: 158, Issue:49 Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Humans; Venous Thromboembolism	2017
Progress in the research on venous thromboembolism. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2017, Volume: 37, Issue:6 Topics: Anticoagulants; Blood Coagulation Factors; Computed Tomography Angiography; Dabigatran; Genetic Predisposition to Disease; Heparin; Humans; Phlebography; Practice Guidelines as Topic; Pulmonary Embolism; Pyridines; Quality of Life; Recurrence; Risk Factors; Thiazoles; Venous Thromboembolism; Venous Thrombosis	2017
Direct oral anticoagulants: An update. Medicina clinica, 2018, 09-14, Volume: 151, Issue:5 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Venous Thromboembolism; Withholding Treatment	2018
The role of direct oral anticoagulants in the management of venous thromboembolism. The American journal of managed care, 2017, Volume: 23, Issue:20 Suppl Topics: Administration, Oral; Anticoagulants; Benzamides; Dabigatran; Female; Humans; Incidence; Male; Prognosis; Pyridines; Risk Assessment; Rivaroxaban; Severity of Illness Index; Survival Rate; Treatment Outcome; Venous Thromboembolism; Warfarin	2017
Novel oral anticoagulants in the preoperative period: a meta-analysis. Journal of thrombosis and thrombolysis, 2018, Volume: 45, Issue:3 Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Preoperative Period; Pyrazoles; Pyridones; Venous Thromboembolism; Warfarin	2018
Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: who, where and for how long? Expert review of respiratory medicine, 2018, Volume: 12, Issue:5 Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism	2018
Novel oral anticoagulants in chronic kidney disease: ready for prime time? Current opinion in nephrology and hypertension, 2018, Volume: 27, Issue:3 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Stroke; Venous Thromboembolism	2018
Update on Direct Oral AntiCoagulants (DOACs). Hamostaseologie, 2017, Volume: 37, Issue:4 Topics: Administration, Oral; Anticoagulants; Dabigatran; Drug Interactions; Drug Substitution; Heparin, Low-Molecular-Weight; Humans; Kidney Function Tests; Liver Function Tests; Metabolic Clearance Rate; Perioperative Care; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles; Venous Thromboembolism	2017
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. The Cochrane database of systematic reviews, 2018, 06-19, Volume: 6 Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Oligosaccharides; Randomized Controlled Trials as Topic; Venous Thromboembolism; Vitamin K	2018
Insights From Practice With Use of Direct Oral Anticoagulants in Transplantation. Progress in transplantation (Aliso Viejo, Calif.), 2018, Volume: 28, Issue:4 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Female; Humans; Male; Middle Aged; Organ Transplantation; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Venous Thromboembolism	2018
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thrombosis and haemostasis, 2019, Volume: 119, Issue:1 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Atrial Fibrillation; Benzamides; Biomarkers; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Drug Administration Schedule; Factor Xa; Heart Diseases; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Risk; Rivaroxaban; Stroke; Thiazoles; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin	2019
Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials. Drugs, 2019, Volume: 79, Issue:6 Topics: Administration, Oral; Anticoagulants; Benzamides; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism	2019
Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study. Blood transfusion = Trasfusione del sangue, 2020, Volume: 18, Issue:1 Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Dabigatran; Glycosaminoglycans; Hemorrhage; Humans; Middle Aged; Pyrazoles; Pyridones; Recurrence; Risk Factors; Rivaroxaban; Treatment Outcome; Venous Thromboembolism; Vitamin K	2020
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 2019, 07-16, Volume: 8, Issue:14 Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin	2019
Novel oral anticoagulants: a review of the literature and considerations in special clinical situations. Hospital practice (1995), 2013, Volume: 41, Issue:1 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Approval; Europe; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Venous Thromboembolism; Warfarin	2013
[Prophylaxis of venous thromboembolism in orthopedic surgery. Role of the new anticoagulants]. Medicina clinica, 2012, Volume: 139 Suppl 2 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2012
[New evidence in the secondary prevention of thromboembolic disease]. Medicina clinica, 2012, Volume: 139 Suppl 2 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Biomarkers; Dabigatran; Fibrin Fibrinogen Degradation Products; Humans; Morpholines; Prognosis; Risk Factors; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thromboembolism	2012
[Recommendations on use of direct oral anticoagulants in the perioperative period]. Medicina clinica, 2012, Volume: 139 Suppl 2 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Dabigatran; Humans; Morpholines; Perioperative Care; Postoperative Hemorrhage; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Withholding Treatment	2012
New anticoagulants for the treatment of venous thromboembolism. Minerva medica, 2013, Volume: 104, Issue:2 Topics: Anticoagulants; Antithrombins; Benzimidazoles; Biotin; Dabigatran; Humans; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Thiazoles; Venous Thromboembolism; Vitamin K	2013
Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison. Chest, 2013, Volume: 144, Issue:2 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism	2013
Venous thromboembolism management: where do novel anticoagulants fit? Current medical research and opinion, 2013, Volume: 29, Issue:7 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor X; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin	2013
Thromboprophylaxis in patients with pelvic and acetabular fractures: A short review and recommendations. Injury, 2013, Volume: 44, Issue:12 Topics: Acetabulum; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Fondaparinux; Fractures, Bone; Heparin; Humans; Mass Screening; Morpholines; Multiple Trauma; Pelvis; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Vena Cava Filters; Venous Thromboembolism	2013
Novel oral anticoagulants: a review of new agents. Postgraduate medicine, 2013, Volume: 125, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Postoperative Complications; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis	2013
New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism. Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Heparin, Low-Molecular-Weight; Humans; Morpholines; Neoplasms; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin	2013
New oral anticoagulants for the treatment of venous thromboembolism. Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2 Topics: Administration, Oral; Adult; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Middle Aged; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin	2013
Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery. Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Heparin, Low-Molecular-Weight; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin	2013
NOACs for thromboprophylaxis in medical patients. Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2 Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Enoxaparin; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Venous Thromboembolism; Warfarin	2013
New oral anticoagulants in elderly patients. Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin	2013
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation. Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2 Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin	2013
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ (Clinical research ed.), 2013, Aug-30, Volume: 347 Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K	2013
Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. Annals of internal medicine, 2013, Aug-20, Volume: 159, Issue:4 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Comparative Effectiveness Research; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; Venous Thromboembolism; Venous Thrombosis	2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation, 2013, Nov-19, Volume: 128, Issue:21 Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Transfusion; Dabigatran; Female; Hemoglobins; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Risk Factors; Treatment Outcome; Venous Thromboembolism; Warfarin	2013
New oral anticoagulants--a review. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2013, Oct-01, Volume: 133, Issue:18 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis	2013
The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities. European journal of internal medicine, 2014, Volume: 25, Issue:1 Topics: Age Factors; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Fondaparinux; Humans; Male; Morpholines; Obesity; Polysaccharides; Postthrombotic Syndrome; Pulmonary Embolism; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Sex Factors; Thiophenes; Thrombophilia; Ultrasonography; Venous Thromboembolism; Venous Thrombosis; Warfarin	2014
Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Vascular health and risk management, 2013, Volume: 9 Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; Chi-Square Distribution; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Enoxaparin; Humans; Myocardial Infarction; Odds Ratio; Pyridines; Risk Assessment; Risk Factors; Stroke; Treatment Outcome; Venous Thromboembolism; Warfarin	2013
An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. Journal of the American Heart Association, 2013, Oct-23, Volume: 2, Issue:5 Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Risk Assessment; Stroke; Venous Thromboembolism; Warfarin	2013
The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. Expert review of hematology, 2013, Volume: 6, Issue:6 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2013
Practical management of new oral anticoagulants after total hip or total knee arthroplasty. Musculoskeletal surgery, 2013, Volume: 97, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Blood Coagulation Tests; Clinical Trials, Phase III as Topic; Contraindications; Dabigatran; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Hematoma, Epidural, Spinal; Humans; Morpholines; Platelet Aggregation Inhibitors; Postoperative Complications; Postoperative Hemorrhage; Postoperative Nausea and Vomiting; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2013
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:3 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K	2014
New oral anticoagulant agents - general features and outcomes in subsets of patients. Thrombosis and haemostasis, 2014, Apr-01, Volume: 111, Issue:4 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin	2014
Increased risk of myocardial infarction with dabigatran: fact or fiction? Journal of cardiovascular medicine (Hagerstown, Md.), 2014, Volume: 15, Issue:1 Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Myocardial Infarction; Risk Assessment; Risk Factors; Stroke; Treatment Outcome; Venous Thromboembolism	2014
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. European heart journal, 2014, Jul-21, Volume: 35, Issue:28 Topics: Acute Disease; Administration, Oral; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Long-Term Care; Morpholines; Perioperative Care; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K	2014
Dabigatran etexilate for venous thromboembolism: a safety evaluation. Expert opinion on drug safety, 2014, Volume: 13, Issue:5 Topics: Benzimidazoles; Contraindications; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Pyridines; Venous Thromboembolism	2014
Risk of major bleeding and the standard doses of dabigatran. European journal of internal medicine, 2014, Volume: 25, Issue:6 Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Risk; Stroke; Venous Thromboembolism	2014
The newer direct oral anticoagulants: a practical guide. Clinical medicine (London, England), 2014, Volume: 14, Issue:2 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin	2014
Anticoagulation: a GP primer on the new oral anticoagulants. Australian family physician, 2014, Volume: 43, Issue:5 Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; General Practice; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin	2014
Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results. Advances in therapy, 2014, Volume: 31, Issue:5 Topics: Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Outcome Assessment, Health Care; Patient Acuity; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism	2014
Direct oral anticoagulants in the prevention of venous thromboembolism: evidence from major clinical trials. Seminars in hematology, 2014, Volume: 51, Issue:2 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Half-Life; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Vitamin K	2014
Direct oral anticoagulants in the management of venous thromboembolism--evidence from major clinical trials. Seminars in hematology, 2014, Volume: 51, Issue:2 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism	2014
Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. Journal of the American Heart Association, 2014, Jun-06, Volume: 3, Issue:3 Topics: Benzimidazoles; Cardiovascular Diseases; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Mortality; Myocardial Infarction; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Venous Thromboembolism	2014
Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood, 2014, Aug-14, Volume: 124, Issue:7 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism	2014
Newer clinically available antithrombotics and their antidotes. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2014, Volume: 40, Issue:3 Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism	2014
Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2014, Volume: 48, Issue:5 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism	2014
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood, 2014, Sep-18, Volume: 124, Issue:12 Topics: Acute Disease; Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Vitamin K	2014
Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients. Mayo Clinic proceedings, 2014, Volume: 89, Issue:7 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism	2014
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. The Cochrane database of systematic reviews, 2014, Jul-08, Issue:7 Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Oligosaccharides; Randomized Controlled Trials as Topic; Venous Thromboembolism; Vitamin K	2014
Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thrombosis research, 2014, Volume: 134, Issue:4 Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism	2014
Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis. International angiology : a journal of the International Union of Angiology, 2014, Volume: 33, Issue:4 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Chi-Square Distribution; Dabigatran; Hemorrhage; Humans; Morpholines; Odds Ratio; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism	2014
Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations. Postgraduate medical journal, 2014, Volume: 90, Issue:1067 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Evidence-Based Medicine; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Venous Thromboembolism; Vitamin K; Warfarin	2014
Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach. Clinical therapeutics, 2014, Oct-01, Volume: 36, Issue:10 Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism; Warfarin	2014
The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism. Current medical research and opinion, 2014, Volume: 30, Issue:11 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis	2014
Target-specific oral anticoagulants: practice issues for the clinician. Hospital practice (1995), 2014, Volume: 42, Issue:3 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin	2014
Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence. Drugs, 2014, Volume: 74, Issue:15 Topics: Acute Disease; Administration, Oral; Benzimidazoles; Dabigatran; Humans; Pyridines; Recurrence; Venous Thromboembolism	2014
Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation. International journal of clinical pharmacology and therapeutics, 2015, Volume: 53, Issue:3 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Patient Safety; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism	2015
New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities. Drugs, 2014, Volume: 74, Issue:17 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism	2014
Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. Thrombosis and haemostasis, 2015, Volume: 113, Issue:2 Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Heparin; Humans; Male; Orthopedic Procedures; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thromboembolism; Treatment Outcome; Venous Thromboembolism; Vitamin K	2015
A systematic review and adjusted indirect comparison of oral anticoagulants. Orthopedics, 2014, Volume: 37, Issue:11 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2014
Review of race/ethnicity in non vitamin K antagonist oral anticoagulants clinical trials. Journal of thrombosis and thrombolysis, 2015, Volume: 39, Issue:2 Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Dabigatran; Ethnicity; Health Equity; Humans; Randomized Controlled Trials as Topic; Venous Thromboembolism	2015
Balancing ischaemia and bleeding risks with novel oral anticoagulants. Nature reviews. Cardiology, 2014, Volume: 11, Issue:12 Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemia; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism	2014
Approach to the new oral anticoagulants in family practice: part 1: comparing the options. Canadian family physician Medecin de famille canadien, 2014, Volume: 60, Issue:11 Topics: Acute Disease; Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Family Practice; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin	2014
Non-vitamin K antagonist oral anticoagulants in atrial fibrillation and venous thromboembolism: where are we now? Hospital practice (1995), 2014, Volume: 42, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biomedical Research; Dabigatran; Factor Xa Inhibitors; Humans; Venous Thromboembolism	2014
Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin? Annual review of medicine, 2015, Volume: 66 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin	2015
Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease. Current opinion in nephrology and hypertension, 2015, Volume: 24, Issue:2 Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Renal Insufficiency, Chronic; Venous Thromboembolism; Vitamin K	2015
Clinical experience with the new oral anticoagulants for treatment of venous thromboembolism. Arteriosclerosis, thrombosis, and vascular biology, 2015, Volume: 35, Issue:3 Topics: Administration, Oral; Animals; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism	2015
Cancer-associated thrombosis: investigating the role of new oral anticoagulants. Thrombosis research, 2015, Volume: 135, Issue:5 Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Recurrence; Thiazoles; Thrombin; Venous Thromboembolism	2015
Using new oral anticoagulants in patients undergoing major orthopedic surgery. Current rheumatology reports, 2015, Volume: 17, Issue:4 Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Orthopedic Procedures; Postoperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism	2015
Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran. Vascular health and risk management, 2015, Volume: 11 Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Comorbidity; Dabigatran; Hemorrhage; Humans; Renal Dialysis; Renal Insufficiency, Chronic; Risk Assessment; Venous Thromboembolism; Vitamin K	2015
Antidotes to non-vitamin K oral anticoagulants: necessary or not? Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:11 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism	2015
Dosing of Target-Specific Oral Anticoagulants in Special Populations. The Annals of pharmacotherapy, 2015, Volume: 49, Issue:9 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Humans; Kidney Diseases; Liver Diseases; Obesity; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism	2015
Dabigatran for the treatment of venous thromboembolism. Expert review of hematology, 2015, Volume: 8, Issue:4 Topics: Antithrombins; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Treatment Outcome; Venous Thromboembolism	2015
Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran. Drug design, development and therapy, 2015, Volume: 9 Topics: Anticoagulants; Antithrombins; Dabigatran; Hemorrhage; Humans; Pulmonary Embolism; Venous Thromboembolism; Venous Thrombosis	2015
[Direct acting oral anticoagulants in venous thromboembolism]. Praxis, 2015, Jul-22, Volume: 104, Issue:15 Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Contraindications; Dabigatran; Drug Interactions; Humans; International Normalized Ratio; Male; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thiophenes; Venous Thromboembolism	2015
Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in elderly elective postarthroplasty patients. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2015, Volume: 26, Issue:8 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dabigatran; Female; Heparin, Low-Molecular-Weight; Humans; Male; Odds Ratio; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Survival Analysis; Treatment Outcome; Venous Thromboembolism	2015
Treatment of pulmonary embolism. Presse medicale (Paris, France : 1983), 2015, Volume: 44, Issue:12 Pt 2 Topics: Antithrombins; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Venous Thromboembolism	2015
Target-specific Oral Anticoagulants in the Emergency Department. The Journal of emergency medicine, 2016, Volume: 50, Issue:2 Topics: Acute Disease; Administration, Oral; Anticoagulants; Blood Coagulation Tests; Dabigatran; Drug Interactions; Drug Monitoring; Emergency Service, Hospital; Factor Xa Inhibitors; Hemorrhage; Humans; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism	2016
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. The Cochrane database of systematic reviews, 2015, Dec-04, Issue:12 Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Secondary Prevention; Thiazoles; Venous Thromboembolism; Venous Thrombosis	2015
Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. PloS one, 2015, Volume: 10, Issue:12 Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome; Venous Thromboembolism	2015
New Oral Anticoagulants in Prophylaxis of Venous Thromboembolic Disease in Major Orthopedic Surgery. Cardiovascular & hematological disorders drug targets, 2016, Volume: 15, Issue:3 Topics: Administration, Oral; Anticoagulants; Dabigatran; Enoxaparin; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Orthopedic Procedures; Polysaccharides; Rivaroxaban; Venous Thromboembolism	2016
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy. The Annals of pharmacotherapy, 2016, Volume: 50, Issue:6 Topics: Administration, Oral; Anticoagulants; Dabigatran; Drug Interactions; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis	2016
Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence. Clinical therapeutics, 2016, Volume: 38, Issue:3 Topics: Anticoagulants; Cost-Benefit Analysis; Dabigatran; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Secondary Prevention; United Kingdom; Venous Thromboembolism	2016
Direct oral anticoagulants: a guide for daily practice. Swiss medical weekly, 2016, Volume: 146 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism	2016
Considerations for Prescribing Target-Specific Oral Anticoagulants in the Setting of Renal Dysfunction or Drug Interactions. Connecticut medicine, 2016, Volume: 80, Issue:2 Topics: Administration, Oral; Anticoagulants; Dabigatran; Drug Interactions; Humans; Outpatients; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Thiazoles; Venous Thromboembolism	2016
Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A meta-analysis of the interventional trials. International journal of cardiology, 2016, Jun-01, Volume: 212 Topics: Administration, Oral; Anticoagulants; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Sex Characteristics; Thiazoles; Treatment Outcome; Venous Thromboembolism	2016
Treatment of Venous Thromboembolism With New Anticoagulant Agents. Journal of the American College of Cardiology, 2016, Apr-26, Volume: 67, Issue:16 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heparin, Low-Molecular-Weight; Humans; Infusions, Intravenous; Male; Middle Aged; Phlebography; Prognosis; Pulmonary Embolism; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Severity of Illness Index; Survival Analysis; Thiazoles; Treatment Outcome; Venous Thromboembolism	2016
The discovery of dabigatran etexilate for the treatment of venous thrombosis. Expert opinion on drug discovery, 2016, Volume: 11, Issue:7 Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Dabigatran; Disease Models, Animal; Drug Interactions; Humans; Venous Thromboembolism; Warfarin	2016
Reversal of dabigatran by idarucizumab: when and how? Expert review of hematology, 2016, Volume: 9, Issue:6 Topics: Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Disease Management; Drug Discovery; Drug Evaluation, Preclinical; Hemorrhage; Humans; Venous Thromboembolism	2016
New anticoagulants for the treatment of venous thromboembolism. Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2016, Volume: 42, Issue:2 Topics: Anticoagulants; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Time Factors; Venous Thromboembolism; Warfarin	2016
Drug Treatment of Venous Thromboembolism in the Elderly. Drugs & aging, 2016, Volume: 33, Issue:7 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Clinical Trials as Topic; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Hemorrhage; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism; Warfarin	2016
[Direct oral anticoagulant associated bleeding]. Journal des maladies vasculaires, 2016, Volume: 41, Issue:4 Topics: Anticoagulants; Antidotes; Atrial Fibrillation; Charcoal; Dabigatran; Hemorrhage; Humans; Prothrombin; Renal Dialysis; Stroke; Venous Thromboembolism	2016
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. American heart journal, 2016, Volume: 177 Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Atrial Fibrillation; Congresses as Topic; Dabigatran; Drug Monitoring; Factor Xa; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Piperazines; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thiazoles; Thrombin Time; Venous Thromboembolism	2016
Dabigatran in clinical practice: Contemporary overview of the evidence. International journal of cardiology, 2016, Oct-01, Volume: 220 Topics: Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Humans; Intracranial Hemorrhages; Stroke; Venous Thromboembolism; Warfarin	2016
Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. PloS one, 2016, Volume: 11, Issue:8 Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Long-Term Care; Network Meta-Analysis; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Treatment Outcome; Venous Thromboembolism	2016
Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants. Polskie Archiwum Medycyny Wewnetrznej, 2016, Sep-05, Volume: 126, Issue:9 Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Clinical Trials, Phase III as Topic; Coagulants; Dabigatran; Humans; Patient Safety; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism	2016
The Prevention of Venous Thromboembolism in Surgical Patients. Advances in experimental medicine and biology, 2017, Volume: 906 Topics: Age Factors; Anticoagulants; Communicable Diseases; Dabigatran; Dehydration; Fondaparinux; Heparin, Low-Molecular-Weight; Hormone Replacement Therapy; Humans; Neoplasms; Obesity; Polysaccharides; Primary Prevention; Pulmonary Embolism; Risk Factors; Surgical Procedures, Operative; Venous Thromboembolism; Venous Thrombosis	2017
The Role of New Oral Anticoagulants (NOACs) in Cancer Patients. Advances in experimental medicine and biology, 2017, Volume: 906 Topics: Administration, Oral; Anticoagulants; Antithrombins; Catheters, Indwelling; Dabigatran; Drug Administration Schedule; Drug Dosage Calculations; Humans; Neoplasms; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis	2017
Best Clinical Practice: Current Controversies in Pulmonary Embolism Imaging and Treatment of Subsegmental Thromboembolic Disease. The Journal of emergency medicine, 2017, Volume: 52, Issue:2 Topics: Anticoagulants; Dabigatran; Decision Making; Humans; Patient Outcome Assessment; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles; Tomography, X-Ray Computed; Venous Thromboembolism	2017
Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis. The Journal of arthroplasty, 2017, Volume: 32, Issue:2 Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Dabigatran; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2017
Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. Circulation, 2017, Mar-07, Volume: 135, Issue:10 Topics: American Heart Association; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; United States; Venous Thromboembolism	2017
Clinical implications of reversal agents for direct oral anticoagulants. Future cardiology, 2017, Volume: 13, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Arginine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism	2017
Reversal of Direct Oral Anticoagulants: Current Status and Future Directions. Seminars in respiratory and critical care medicine, 2017, Volume: 38, Issue:1 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa; Forecasting; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism	2017
Anticoagulation Therapy and NOACs in Heart Failure. Handbook of experimental pharmacology, 2017, Volume: 243 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Heart Failure; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin	2017
The top 4 advances in antithrombotic care in the last year. Thrombosis research, 2008, Volume: 123 Suppl 1 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2008
Brave new world: the current and future use of novel anticoagulants. Thrombosis research, 2008, Volume: 123 Suppl 1 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism	2008
[Anaesthesia and thromboembolic disease]. Medicina clinica, 2008, Volume: 131 Suppl 2 Topics: Acenocoumarol; Administration, Oral; Anesthesia, Conduction; Anticoagulants; Benzimidazoles; Clinical Protocols; Dabigatran; Early Ambulation; Fibrinolytic Agents; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Polysaccharides; Postoperative Complications; Pyridines; Risk Factors; Rivaroxaban; Safety; Surgical Procedures, Operative; Thiophenes; Venous Thromboembolism; Venous Thrombosis	2008
Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thrombosis and haemostasis, 2009, Volume: 101, Issue:1 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Enoxaparin; Hemorrhage; Humans; Pyridines; Risk Assessment; Treatment Outcome; Venous Thromboembolism	2009
Emergence of new oral antithrombotics: a critical appraisal of their clinical potential. Vascular health and risk management, 2008, Volume: 4, Issue:6 Topics: Administration, Oral; Benzimidazoles; Blood Coagulation; Dabigatran; Fibrinolytic Agents; Hemorrhage; History, 20th Century; History, 21st Century; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2008
New anticoagulants for prevention and treatment of venous thromboembolism. Current vascular pharmacology, 2010, Volume: 8, Issue:3 Topics: Animals; Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drugs, Investigational; Humans; Morpholines; Oligosaccharides; Pyridines; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2010
A logical approach to surgical thromboprophylaxis. Current opinion in hematology, 2009, Volume: 16, Issue:5 Topics: Benzimidazoles; Dabigatran; Humans; Morpholines; Postoperative Complications; Premedication; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism	2009
Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal. Health technology assessment (Winchester, England), 2009, Volume: 13 Suppl 2 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Trials as Topic; Comparative Effectiveness Research; Cost-Benefit Analysis; Dabigatran; Elective Surgical Procedures; Enoxaparin; Fondaparinux; Humans; Polysaccharides; Pyridines; Quality-Adjusted Life Years; Venous Thromboembolism	2009
Anticoagulation with {blacktriangledown}dabigatran or{blacktriangledown}rivaroxaban. Drug and therapeutics bulletin, 2009, Volume: 47, Issue:10 Topics: Adult; Anticoagulants; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2009
New oral anticoagulants: a practical guide for clinicians. Journal of thrombosis and thrombolysis, 2010, Volume: 29, Issue:2 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Drugs, Investigational; Evidence-Based Medicine; Humans; Morpholines; Orthopedic Procedures; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2010
Dabigatran etexilate in venous thromboembolism. Drugs of today (Barcelona, Spain : 1998), 2009, Volume: 45, Issue:10 Topics: Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Humans; Pyridines; Venous Thromboembolism	2009
[Dabigatran: a new therapeutic option for therapy and prophylaxis of thromboembolic diseases?]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:6 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Approval; Half-Life; Humans; Metabolic Clearance Rate; Multicenter Studies as Topic; Postoperative Complications; Prodrugs; Pyridines; Randomized Controlled Trials as Topic; Thrombin; Venous Thromboembolism	2010
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thrombosis and haemostasis, 2010, Volume: 103, Issue:6 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Blood Coagulation; Cerebral Hemorrhage; Charcoal; Dabigatran; Drug Overdose; Humans; International Normalized Ratio; Pyridines; Sensitivity and Specificity; Thrombin; Thrombin Time; Treatment Outcome; Venous Thromboembolism	2010
Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement. The Cochrane database of systematic reviews, 2010, Apr-14, Issue:4 Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzimidazoles; Benzylamines; Contraindications; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Pyridines; Randomized Controlled Trials as Topic; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin	2010
Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. Croatian medical journal, 2010, Volume: 51, Issue:2 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Enoxaparin; Hemorrhage; Humans; Morpholines; Postoperative Care; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Safety; Survival Analysis; Thiophenes; Venous Thromboembolism	2010
New oral anticoagulants in development: potential for improved safety profiles. Reviews in neurological diseases, 2010, Volume: 7, Issue:1 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Blood Coagulation; Dabigatran; Drug Evaluation; Factor Xa; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Venous Thromboembolism	2010
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thrombosis research, 2010, Volume: 126, Issue:3 Topics: Administration, Oral; Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Chi-Square Distribution; Dabigatran; Double-Blind Method; Drug Administration Schedule; Elective Surgical Procedures; Enoxaparin; Evidence-Based Medicine; Female; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Odds Ratio; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Venous Thromboembolism	2010
New aspects on treatment modalities for thromboembolic episodes. Journal of internal medicine, 2010, Volume: 268, Issue:2 Topics: Anticoagulants; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Glycosaminoglycans; Humans; Outpatient Clinics, Hospital; Pyridines; Thrombin; Thrombolytic Therapy; Venous Thromboembolism	2010
Clot prevention--common questions about medications. Australian family physician, 2010, Volume: 39, Issue:7 Topics: Anticoagulants; Aspirin; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; International Normalized Ratio; Morpholines; Pharmacogenetics; Pyridines; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Venous Thromboembolism	2010
Dabigatran: the anticoagulant we have long expected? Recent patents on cardiovascular drug discovery, 2010, Volume: 5, Issue:3 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Venous Thromboembolism	2010
New anticoagulants for the prevention of thromboembolism. Current pharmaceutical design, 2010, Volume: 16, Issue:31 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2010
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data. Pharmacology & therapeutics, 2011, Volume: 129, Issue:2 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Humans; Pyridines; Stroke; Thrombin; Venous Thromboembolism; Warfarin	2011
New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors. Clinics in chest medicine, 2010, Volume: 31, Issue:4 Topics: Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Fondaparinux; Humans; Morpholines; Oligosaccharides; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism	2010
Intracerebral hemorrhage: Pick your poison. Cleveland Clinic journal of medicine, 2010, Volume: 77, Issue:11 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Chronic Disease; Dabigatran; Humans; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Venous Thromboembolism; Warfarin	2010
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. Journal of clinical pharmacy and therapeutics, 2011, Volume: 36, Issue:1 Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis	2011
Direct thrombin inhibitors. British journal of clinical pharmacology, 2011, Volume: 72, Issue:4 Topics: Anticoagulants; Antithrombins; Arginine; Benzimidazoles; Dabigatran; Hirudins; Humans; Peptide Fragments; Pipecolic Acids; Pyridines; Recombinant Proteins; Sulfonamides; Thrombin; Venous Thromboembolism	2011
Pharmacoeconomics of dabigatran etexilate for prevention of thromboembolism after joint replacement surgery. Expert review of pharmacoeconomics & outcomes research, 2011, Volume: 11, Issue:1 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Economics, Pharmaceutical; Humans; Pyridines; Venous Thromboembolism	2011
New anticoagulants: pharmacology and clinical studies. Wiener medizinische Wochenschrift (1946), 2011, Volume: 161, Issue:3-4 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Postoperative Complications; Prothrombin; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2011
Direct thrombin and factor Xa inhibitors in children: a quest for new anticoagulants for children. Wiener medizinische Wochenschrift (1946), 2011, Volume: 161, Issue:3-4 Topics: Adolescent; Anticoagulants; Arginine; Benzimidazoles; beta-Alanine; Child; Child, Preschool; Dabigatran; Drug Approval; Factor Xa Inhibitors; Fondaparinux; Hirudins; Humans; Infant; Infant, Newborn; Morpholines; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Risk Factors; Rivaroxaban; Sulfonamides; Thiophenes; Thrombin; Venous Thromboembolism	2011
Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. European heart journal, 2011, Volume: 32, Issue:16 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Approval; Factor X; Humans; Morpholines; Off-Label Use; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism	2011
Dabigatran as anticoagulant therapy for atrial fibrillation. Which patients should receive it, which patients may not need it, and other practical aspects of patient management. Polskie Archiwum Medycyny Wewnetrznej, 2011, Volume: 121, Issue:3 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome; Venous Thromboembolism	2011
Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists? Hospital practice (1995), 2011, Volume: 39, Issue:1 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Interactions; Heparinoids; Humans; Pulmonary Embolism; Pyridines; Stroke; Venous Thromboembolism; Vitamin K	2011
Preventing postsurgical venous thromboembolism: pharmacological approaches. Seminars in thrombosis and hemostasis, 2011, Volume: 37, Issue:3 Topics: Aged; Anticoagulants; Antithrombins; Arthroscopy; Bariatric Surgery; Benzimidazoles; Blood Coagulation Disorders, Inherited; Dabigatran; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Hip Fractures; Humans; Kidney; Knee; Laparoscopy; Morpholines; Neoplasms; Orthopedic Procedures; Polysaccharides; Postoperative Complications; Pyridines; Rivaroxaban; Thiophenes; Thrombophilia; Venous Thromboembolism	2011
Dabigatran etexilate: a new oral thrombin inhibitor. Circulation, 2011, Apr-05, Volume: 123, Issue:13 Topics: Administration, Oral; Animals; Anticoagulants; Antithrombin Proteins; Benzimidazoles; Dabigatran; Humans; Prodrugs; Pyridines; Randomized Controlled Trials as Topic; Thrombin; Venous Thromboembolism	2011
New oral anticoagulants and outpatient prophylaxis of venous thromboembolism. The American journal of managed care, 2011, Volume: 17, Issue:1 Suppl Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Guideline Adherence; Heparin, Low-Molecular-Weight; Humans; Morpholines; Outpatients; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Time Factors; Venous Thromboembolism; Warfarin	2011
Characteristics of novel anticoagulants and potential economic implications. The American journal of managed care, 2011, Volume: 17, Issue:1 Suppl Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Cost Savings; Dabigatran; Health Care Costs; Humans; Medication Adherence; Morpholines; Rivaroxaban; Thiophenes; United States; Venous Thromboembolism; Vitamin K	2011
A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery. Drug safety, 2011, Jun-01, Volume: 34, Issue:6 Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Orthopedic Procedures; Risk Assessment; Venous Thromboembolism	2011
[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future]. Medecine sciences : M/S, 2011, Volume: 27, Issue:5 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Approval; Drug Monitoring; Factor Xa Inhibitors; Fibrinolytic Agents; Forecasting; France; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Thrombophilia; Venous Thromboembolism	2011
Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux. International angiology : a journal of the International Union of Angiology, 2011, Volume: 30, Issue:3 Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Evidence-Based Medicine; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Polysaccharides; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2011
Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants. Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:9 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism	2011
Dabigatran etexilate: A novel oral direct thrombin inhibitor. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2011, Aug-15, Volume: 68, Issue:16 Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Monitoring; Humans; Prodrugs; Pyridines; Stroke; Thrombin; United States; Venous Thromboembolism	2011
[The new Anticoagulants - Relevant Facts for the GP]. Praxis, 2011, Aug-10, Volume: 100, Issue:16 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Evidence-Based Medicine; Factor Xa Inhibitors; General Practice; Humans; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2011
Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice. Hospital practice (1995), 2011, Volume: 39, Issue:3 Topics: Antithrombins; Benzimidazoles; Blood Coagulation Tests; Cardiovascular Diseases; Clinical Trials as Topic; Dabigatran; Dose-Response Relationship, Drug; Enoxaparin; Humans; Pyridines; Venous Thromboembolism; Warfarin	2011
Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials. Orthopedics, 2011, Volume: 34, Issue:10 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2011
Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor. Journal of cardiothoracic and vascular anesthesia, 2011, Volume: 25, Issue:6 Topics: Anesthesia, Conduction; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chemistry, Pharmaceutical; Dabigatran; Fondaparinux; Heart Valve Prosthesis Implantation; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Polysaccharides; Randomized Controlled Trials as Topic; Thrombin; Venous Thromboembolism; Vitamin K	2011
Dabigatran: a review of clinical and pharmacoeconomic evidence. Critical pathways in cardiology, 2011, Volume: 10, Issue:3 Topics: Antithrombin Proteins; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Economics, Pharmaceutical; Humans; Pyridines; Quality of Life; Venous Thromboembolism	2011
Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected]. International orthopaedics, 2012, Volume: 36, Issue:4 Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Dabigatran; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Humans; Prospective Studies; Randomized Controlled Trials as Topic; Renal Insufficiency; Venous Thromboembolism	2012
Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial. Seminars in vascular surgery, 2011, Volume: 24, Issue:3 Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Randomized Controlled Trials as Topic; Venous Thromboembolism; Warfarin	2011
Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal. PharmacoEconomics, 2012, Feb-01, Volume: 30, Issue:2 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Humans; Pyridines; Randomized Controlled Trials as Topic; United Kingdom; Venous Thromboembolism	2012
A new approach with anticoagulant development: tailoring anticoagulant therapy with dabigatran etexilate according to patient risk. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:2 Topics: Anticoagulants; Benzimidazoles; Dabigatran; Hemorrhage; Humans; Orthopedic Procedures; Pyridines; Risk Factors; Venous Thromboembolism; Venous Thrombosis	2012
New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders. Vascular health and risk management, 2012, Volume: 8 Topics: Administration, Oral; Animals; Antithrombins; Arterial Occlusive Diseases; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Fibrinolytic Agents; Humans; Risk Factors; Thromboembolism; Treatment Outcome; Venous Thromboembolism	2012
Improving prevention and treatment of venous thromboembolism: clinical trial results. Journal of medical economics, 2012, Volume: 15, Issue:4 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Economics, Pharmaceutical; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2012
The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2012, Volume: 18, Issue:6 Topics: Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2012
Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2012, Volume: 18, Issue:5 Topics: Acute Coronary Syndrome; Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin	2012
New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation. Journal of internal medicine, 2012, Volume: 271, Issue:6 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Drugs, Investigational; Heparin; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K	2012
Thromboembolic prophylaxis in orthopedic surgery using dabigatran: an oral direct thrombin inhibitor. Expert review of cardiovascular therapy, 2012, Volume: 10, Issue:4 Topics: Antithrombins; Benzimidazoles; Canada; Clinical Trials as Topic; Dabigatran; European Union; Humans; Orthopedics; Pyridines; Treatment Outcome; Venous Thromboembolism	2012
Long-term benefits of preventing venous thromboembolic events. Current medical research and opinion, 2012, Volume: 28, Issue:6 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Follow-Up Studies; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism	2012
[Pharmacological sheet. Dabigatran, oral administration (Pradaxa)]. Journal de pharmacie de Belgique, 2012, Issue:1 Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Fibrinolytic Agents; Humans; Thrombosis; Venous Thromboembolism	2012
Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery. Drugs, 2012, May-07, Volume: 72, Issue:7 Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Postoperative Complications; Pyridines; Randomized Controlled Trials as Topic; Venous Thromboembolism	2012
Treatment of venous thromboembolism with dabigatran. Current opinion in pulmonary medicine, 2012, Volume: 18, Issue:5 Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Rivaroxaban; Secondary Prevention; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin	2012
Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ (Clinical research ed.), 2012, Jun-14, Volume: 344 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2012
New oral anticoagulants in the ED setting: a review. The American journal of emergency medicine, 2012, Volume: 30, Issue:9 Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Emergency Service, Hospital; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism	2012
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery. Thrombosis and haemostasis, 2012, Volume: 108, Issue:5 Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Endpoint Determination; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2012
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor. Thrombosis and haemostasis, 2012, Volume: 108, Issue:5 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pregnancy; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Warfarin	2012
Performance of new anticoagulants for thromboprophylaxis in patients undergoing hip and knee replacement surgery. Pharmacotherapy, 2012, Volume: 32, Issue:11 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Societies, Medical; Thiazoles; Thiophenes; Venous Thromboembolism	2012
The novel anticoagulants: the surgeons' prospective. Surgery, 2013, Volume: 153, Issue:3 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Surgical Procedures, Operative; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin	2013
New oral therapies for the prevention and treatment of venous thromboembolism. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013, Jan-15, Volume: 70, Issue:2 Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; Dabigatran; Drug Monitoring; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2013
Implications of new anticoagulants in primary practice. International journal of clinical practice, 2013, Volume: 67, Issue:2 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism	2013
Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clinical pharmacokinetics, 2013, Volume: 52, Issue:4 Topics: Absorption; Anticoagulants; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Liver Diseases; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Tissue Distribution; Venous Thromboembolism	2013
The novel oral anticoagulants. Seminars in thrombosis and hemostasis, 2013, Volume: 39, Issue:2 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2013
New anticoagulants for treatment of venous thromboembolism. Arteriosclerosis, thrombosis, and vascular biology, 2008, Volume: 28, Issue:3 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Male; Maximum Tolerated Dose; Morpholines; Oligosaccharides; Postphlebitic Syndrome; Prognosis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Survival Analysis; Thiophenes; Treatment Outcome; Venous Thromboembolism	2008
Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Seminars in thrombosis and hemostasis, 2008, Volume: 34, Issue:1 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Glycine; Humans; Infusions, Parenteral; Morpholines; Oligosaccharides; Piperazines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Venous Thromboembolism	2008
Prevention of venous thromboembolism in the geriatric patient. Cardiology clinics, 2008, Volume: 26, Issue:2 Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Azetidines; Benzimidazoles; Benzylamines; Dabigatran; Elective Surgical Procedures; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Polysaccharides; Prodrugs; Pyridines; Risk Factors; Vena Cava Filters; Venous Thromboembolism	2008

Trials

32 trial(s) available for dabigatran and Thromboembolism, Venous

Article	Year
Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia. Blood advances, 2022, 11-22, Volume: 6, Issue:22 Topics: Child; Dabigatran; Humans; Protein C Deficiency; Recurrence; Risk Factors; Secondary Prevention; Thrombophilia; United States; Venous Thromboembolism	2022
Investigation of dabigatran secretion into breast milk: Implications for oral thromboprophylaxis in post-partum women. American journal of hematology, 2020, Volume: 95, Issue:1 Topics: Antithrombins; Dabigatran; Factor Xa Inhibitors; Female; Fetal Blood; Humans; Infant, Newborn; Male; Milk, Human; Postpartum Period; Venous Thromboembolism	2020
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood, 2020, 02-13, Volume: 135, Issue:7 Topics: Adolescent; Child; Child, Preschool; Dabigatran; Endpoint Determination; Female; Follow-Up Studies; Humans; Infant; Kaplan-Meier Estimate; Male; Risk Factors; Secondary Prevention; Time Factors; Venous Thromboembolism	2020
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. The Lancet. Haematology, 2021, Volume: 8, Issue:1 Topics: Acute Disease; Administration, Oral; Adolescent; Anticoagulants; Child; Child, Preschool; Dabigatran; Disease-Free Survival; Female; Humans; Infant; Male; Survival Rate; Venous Thromboembolism	2021
Bleeding complications of thromboprophylaxis with dabigatran, nadroparin or rivaroxaban for 6 weeks after total knee arthroplasty surgery: a randomised pilot study. BMJ open, 2021, 01-18, Volume: 11, Issue:1 Topics: Activities of Daily Living; Anticoagulants; Arthroplasty, Replacement, Knee; Dabigatran; Female; Humans; Nadroparin; Netherlands; Pilot Projects; Postoperative Care; Postoperative Complications; Quality of Life; Rivaroxaban; Treatment Outcome; Venous Thromboembolism	2021
Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients. Journal of thrombosis and haemostasis : JTH, 2021, Volume: 19, Issue:10 Topics: Anticoagulants; Cross-Sectional Studies; Dabigatran; Follow-Up Studies; Humans; Postthrombotic Syndrome; Quality of Life; Venous Thromboembolism; Warfarin	2021
Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. The Lancet. Haematology, 2021, Volume: 8, Issue:9 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Drug Administration Schedule; Female; Follow-Up Studies; Hemorrhage; Heparin; Humans; Male; Middle Aged; Pulmonary Embolism; Risk Factors; Treatment Outcome; Venous Thromboembolism	2021
Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability. Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:11 Topics: Administration, Oral; Age Factors; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Child; Child, Preschool; Dabigatran; Drug Compounding; Drug Monitoring; Female; Hemorrhage; Humans; Infant; Male; Pulmonary Embolism; Recurrence; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis	2017
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism. Thrombosis and haemostasis, 2017, Volume: 117, Issue:11 Topics: Administration, Oral; Age Factors; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Compounding; Drug Monitoring; Female; France; Hemorrhage; Humans; Infant; Linear Models; Male; Nonlinear Dynamics; Ontario; Pharmaceutical Solutions; Russia; Treatment Outcome; Venous Thromboembolism	2017
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. Lancet (London, England), 2018, 06-09, Volume: 391, Issue:10137 Topics: Aged; Aged, 80 and over; Antithrombins; Dabigatran; Female; Hemorrhage; Humans; Male; Myocardial Infarction; Omeprazole; Perioperative Period; Peripheral Arterial Disease; Placebo Effect; Proton Pump Inhibitors; Stroke; Thrombosis; Treatment Outcome; Troponin; Venous Thromboembolism	2018
Anticoagulant Effects of Dabigatran in Paediatric Patients Compared with Adults: Combined Data from Three Paediatric Clinical Trials. Thrombosis and haemostasis, 2018, Volume: 118, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Child; Dabigatran; Female; Hemostasis; Humans; Infant; Male; Middle Aged; Partial Thromboplastin Time; Thrombin Time; Venous Thromboembolism; Young Adult	2018
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. The New England journal of medicine, 2013, Feb-21, Volume: 368, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; beta-Alanine; Dabigatran; Female; Follow-Up Studies; Hemorrhage; Humans; Intention to Treat Analysis; International Normalized Ratio; Male; Middle Aged; Recurrence; Risk; Venous Thromboembolism; Warfarin; Young Adult	2013
Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain. Thrombosis and haemostasis, 2013, Volume: 110, Issue:5 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost of Illness; Cost-Benefit Analysis; Dabigatran; Direct Service Costs; Enoxaparin; France; Humans; Italy; Models, Theoretical; Morpholines; Postoperative Complications; Pyridines; Quality of Life; Rivaroxaban; Spain; Thiophenes; Venous Thromboembolism	2013
Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation, 2013, Nov-19, Volume: 128, Issue:21 Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Transfusion; Dabigatran; Female; Hemoglobins; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Risk Factors; Treatment Outcome; Venous Thromboembolism; Warfarin	2013
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation, 2014, Feb-18, Volume: 129, Issue:7 Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Recurrence; Risk Factors; Venous Thromboembolism; Warfarin; Young Adult	2014
Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting. Journal of medical economics, 2016, Volume: 19, Issue:1 Topics: Anticoagulants; Cost-Benefit Analysis; Dabigatran; Double-Blind Method; Female; Health Services; Hemorrhage; Humans; Male; Middle Aged; Models, Econometric; Pulmonary Embolism; Quality-Adjusted Life Years; Rivaroxaban; Venous Thromboembolism; Venous Thrombosis; Warfarin	2016
Bleeding events with dabigatran or warfarin in patients with venous thromboembolism. Thrombosis and haemostasis, 2016, Volume: 115, Issue:2 Topics: Aged; Anticoagulants; Antithrombins; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Risk; Time Factors; Venous Thromboembolism; Warfarin	2016
Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery. Thrombosis research, 2016, Volume: 139 Topics: Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Chromatography, High Pressure Liquid; Dabigatran; Drug Monitoring; Female; Humans; Male; Middle Aged; Orthopedic Procedures; Rivaroxaban; Tandem Mass Spectrometry; Venous Thromboembolism	2016
Thromboprophylaxis with dabigatran after total hip arthroplasty in Indian patients: A subanalysis of a double-blind, double-dummy, randomized RE-NOVATE II study. Asian journal of surgery, 2017, Volume: 40, Issue:2 Topics: Administration, Oral; Aged; Arthroplasty, Replacement, Hip; Confidence Intervals; Dabigatran; Double-Blind Method; Enoxaparin; Female; Follow-Up Studies; Humans; Incidence; India; Injections, Subcutaneous; Male; Middle Aged; Odds Ratio; Postoperative Complications; Primary Prevention; Prospective Studies; Risk Assessment; Treatment Outcome; Venous Thromboembolism	2017
Observational study of dabigatran etexilate 150mg in patients with moderate renal impairment undergoing elective total hip or knee replacement. Thrombosis research, 2016, Volume: 143 Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Renal Insufficiency; Treatment Outcome; Venous Thromboembolism	2016
An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery. Thrombosis research, 2016, Volume: 144 Topics: Aged; Aged, 80 and over; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Canada; Dabigatran; Europe; Female; Humans; Male; Middle Aged; Renal Insufficiency; Venous Thromboembolism; White People	2016
Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. An open-label phase IIa study. Thrombosis and haemostasis, 2016, 08-30, Volume: 116, Issue:3 Topics: Administration, Oral; Adolescent; Antithrombins; Dabigatran; Dose-Response Relationship, Drug; Dyspepsia; Female; Humans; Male; Prodrugs; Venous Thromboembolism	2016
Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II. Thrombosis and haemostasis, 2016, Sep-27, Volume: 116, Issue:4 Topics: Adult; Aged; Anticoagulants; Dabigatran; Female; Humans; Male; Middle Aged; Pulmonary Embolism; Venous Thromboembolism; Venous Thrombosis; Warfarin	2016
Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. The European respiratory journal, 2016, Volume: 48, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Anticoagulants; Cohort Studies; Dabigatran; Data Interpretation, Statistical; Decision Making; Female; Hemorrhage; Humans; Male; Models, Statistical; Regression Analysis; Risk Factors; ROC Curve; Sensitivity and Specificity; Severity of Illness Index; Venous Thromboembolism; Warfarin; Young Adult	2016
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. The Journal of arthroplasty, 2009, Volume: 24, Issue:1 Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Double-Blind Method; Enoxaparin; Europe; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; North America; Outcome Assessment, Health Care; Pyridines; Risk Factors; Thrombin; Venous Thromboembolism	2009
Dabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients with a safety profile comparable to placebo. The Journal of arthroplasty, 2010, Volume: 25, Issue:8 Topics: Administration, Oral; Aged; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fibrinolytic Agents; Humans; Japan; Male; Middle Aged; Pyridines; Treatment Outcome; Venous Thromboembolism	2010
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. The New England journal of medicine, 2009, Dec-10, Volume: 361, Issue:24 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; Dabigatran; Double-Blind Method; Female; Humans; International Normalized Ratio; Male; Middle Aged; Pyridines; Recurrence; Risk; Venous Thromboembolism; Warfarin; Young Adult	2009
[Dabigatran versus warfarin in the treatment of acute venous thromboembolism. Results of the RE-COVER study]. Kardiologiia, 2010, Volume: 50, Issue:3 Topics: Anticoagulants; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Middle Aged; Pyridines; Survival Rate; Treatment Outcome; Venous Thromboembolism; Warfarin	2010
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circulation. Cardiovascular quality and outcomes, 2010, Volume: 3, Issue:6 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Follow-Up Studies; Hemorrhage; Humans; Morpholines; Postoperative Complications; Prospective Studies; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Withholding Treatment	2010
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thrombosis and haemostasis, 2011, Volume: 105, Issue:4* Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Dabigatran; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Postoperative Complications; Survival Analysis; Venous Thromboembolism; Venous Thrombosis	2011
Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials. Thrombosis research, 2012, Volume: 130, Issue:2 Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2012
Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis. Thrombosis research, 2012, Volume: 130, Issue:6 Topics: Aged; Anticoagulants; Antithrombins; Benzimidazoles; Dabigatran; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Humans; Male; Middle Aged; Orthopedic Procedures; Prospective Studies; Pyridines; Treatment Outcome; Venous Thromboembolism	2012

Other Studies

158 other study(ies) available for dabigatran and Thromboembolism, Venous

Article	Year
Mortality associated with the use of non-vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban. Cancer medicine, 2021, Volume: 10, Issue:20 Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Cause of Death; Dabigatran; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Rivaroxaban; Taiwan; Venous Thromboembolism	2021
Thromboembolic and bleeding complications following primary total knee arthroplasty : a Danish nationwide cohort study. The bone & joint journal, 2021, Volume: 103-B, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antithrombins; Arthroplasty, Replacement, Knee; Dabigatran; Dalteparin; Denmark; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Perioperative Care; Postoperative Complications; Postoperative Hemorrhage; Proportional Hazards Models; Registries; Rivaroxaban; Tinzaparin; Venous Thromboembolism; Young Adult	2021
Direct Oral Anticoagulants: Overcoming the Challenges of Managing Venous Thromboembolism in Children. The Journal of pediatrics, 2022, Volume: 240 Topics: Anticoagulants; Child; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Risk Factors; Rivaroxaban; Venous Thromboembolism; Vitamin K	2022
Differential effect of direct oral anticoagulants on thrombin generation and fibrinolysis in patients with atrial fibrillation and venous thromboembolism. Blood transfusion = Trasfusione del sangue, 2022, Volume: 20, Issue:6 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Fibrin Clot Lysis Time; Fibrinolysis; Humans; Rivaroxaban; Thrombin; Tissue Plasminogen Activator; Venous Thromboembolism	2022
Anticoagulation in Pediatric Patients. Hamostaseologie, 2022, Volume: 42, Issue:1 Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Child; Dabigatran; Humans; Rivaroxaban; Venous Thromboembolism	2022
Thromboembolic Events While Taking Direct Oral Anticoagulants: An Analysis of Post-market WHO Database Reports from 2012 to 2020. Clinical drug investigation, 2022, Volume: 42, Issue:7 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pulmonary Embolism; Pyridones; Reproducibility of Results; Rivaroxaban; Venous Thromboembolism; Venous Thrombosis; World Health Organization	2022
Drugs for treatment and prevention of venous thromboembolism. The Medical letter on drugs and therapeutics, 2022, 07-25, Volume: 64, Issue:1655 Topics: Anticoagulants; Dabigatran; Humans; Pyridones; Rivaroxaban; Venous Thromboembolism	2022
Comparison table: Some oral anticoagulants for VTE. The Medical letter on drugs and therapeutics, 2022, 07-25, Volume: 64, Issue:1655 Topics: Administration, Oral; Anticoagulants; Dabigatran; Humans; Pyridones; Rivaroxaban; Venous Thromboembolism	2022
Impact of dabigatran dose on drug levels in asian patients with atrial fibrillation or venous thromboembolism: evidence from pharmacological to clinical outcomes. Journal of thrombosis and thrombolysis, 2023, Volume: 55, Issue:2 Topics: Antithrombins; Atrial Fibrillation; Dabigatran; Female; Humans; Prospective Studies; Stroke; Treatment Outcome; Venous Thromboembolism; Warfarin	2023
Just DOAC: Use of direct-acting oral anticoagulants in pediatrics. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2023, 03-21, Volume: 80, Issue:7 Topics: Administration, Oral; Anticoagulants; Child; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Rivaroxaban; Venous Thromboembolism	2023
The efficacy of direct oral anticoagulants in patients on concomitant treatment with levetiracetam. Scientific reports, 2023, 06-07, Volume: 13, Issue:1 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Levetiracetam; Male; Pyridones; Rivaroxaban; Stroke; Venous Thromboembolism	2023
Utilization outcomes of direct oral anticoagulants in Medicare patients. Research in social & administrative pharmacy : RSAP, 2023, Volume: 19, Issue:11 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Medicare; Retrospective Studies; Rivaroxaban; United States; Venous Thromboembolism; Warfarin	2023
Safety and efficacy of oral anticoagulants in extreme weights. Thrombosis research, 2023, Volume: 231 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Obesity; Pyridones; Rivaroxaban; Thinness; Venous Thromboembolism; Warfarin	2023
Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism. BMC medicine, 2023, 09-29, Volume: 21, Issue:1 Topics: Administration, Oral; Aged; Anticoagulants; Dabigatran; Female; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism	2023
Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia. Orphanet journal of rare diseases, 2019, 08-28, Volume: 14, Issue:1 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Epistaxis; Female; Humans; Male; Middle Aged; Pulmonary Embolism; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Telangiectasia, Hereditary Hemorrhagic; Venous Thromboembolism; Warfarin	2019
Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism. Pharmacotherapy, 2020, Volume: 40, Issue:3 Topics: Administration, Oral; Aged; Anticoagulants; Cohort Studies; Dabigatran; Female; Humans; Male; Middle Aged; Obesity, Morbid; Pulmonary Embolism; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Treatment Outcome; Venous Thromboembolism; Warfarin	2020
The phase 3 pediatric anticoagulant era. Blood, 2020, 02-13, Volume: 135, Issue:7 Topics: Anticoagulants; Child; Dabigatran; Heart Transplantation; Humans; Retrospective Studies; Secondary Prevention; Venous Thromboembolism	2020
Perioperative symptomatic venous thromboembolism after immediate chemoprophylaxis in patients with pelvic and lower-extremity fractures. Scientific reports, 2020, 03-25, Volume: 10, Issue:1 Topics: Adult; Aged; Anticoagulants; Bones of Lower Extremity; Chemoprevention; Dabigatran; Enoxaparin; Female; Fractures, Bone; Humans; Male; Middle Aged; Multidetector Computed Tomography; Pelvic Bones; Pulmonary Embolism; Risk Factors; Sex Factors; Venous Thromboembolism; Venous Thrombosis; Young Adult	2020
Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study. The American journal of medicine, 2020, Volume: 133, Issue:8 Topics: Administration, Oral; Adult; Age Distribution; Aged; Anticoagulants; Asia; Comorbidity; Cross-Sectional Studies; Dabigatran; Diabetes Mellitus; Europe; Factor Xa Inhibitors; Female; Fondaparinux; Heparin; Humans; Hypertension; Latin America; Male; Middle Aged; Middle East; Neoplasms; Postoperative Complications; Practice Patterns, Physicians'; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis; Wounds and Injuries	2020
A Prospective Cohort Comparative Study of Rivaroxaban, Dabigatran, and Apixaban Oral Thromboprophylaxis in 2431 Hip and Knee Arthroplasty Patients: Primary Efficacy Outcomes and Safety Profile. The Journal of arthroplasty, 2020, Volume: 35, Issue:11 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dabigatran; Humans; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism	2020
Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study. Journal of thrombosis and thrombolysis, 2021, Volume: 51, Issue:3 Topics: Age Factors; Aged; Anticoagulants; Antithrombins; Blood Coagulation; Comorbidity; Dabigatran; Female; Global Health; Humans; Kidney Function Tests; Male; Practice Patterns, Physicians'; Renal Insufficiency; Risk Adjustment; Severity of Illness Index; Venous Thromboembolism; Warfarin	2021
Working smarter, not harder: evaluating a population health approach to anticoagulation therapy management. Journal of thrombosis and thrombolysis, 2021, Volume: 52, Issue:1 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Population Health; Venous Thromboembolism	2021
Dabigatran etexilate and treatment of acute venous thromboembolism in children. The Lancet. Haematology, 2021, Volume: 8, Issue:1 Topics: Anticoagulants; Child; Dabigatran; Humans; Venous Thromboembolism; Venous Thrombosis	2021
Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism. Journal of thrombosis and haemostasis : JTH, 2021, Volume: 19, Issue:5 Topics: Adolescent; Adult; Antithrombins; Body Weight; Child; Computer Simulation; Dabigatran; Female; Humans; Male; Venous Thromboembolism	2021
Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication. JAMA internal medicine, 2021, 06-01, Volume: 181, Issue:6 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles; Venous Thromboembolism	2021
Reduced‑dose apixaban and dabigatran in patients with advanced liver cirrhosis and venous thromboembolism: a case series. Polish archives of internal medicine, 2021, 08-30, Volume: 131, Issue:7-8 Topics: Anticoagulants; Dabigatran; Humans; Liver Cirrhosis; Pyrazoles; Pyridones; Venous Thromboembolism	2021
Incidence of abnormal uterine bleeding in a multicenter implementation study using apixaban and rivaroxaban to treat venous thromboembolism. Thrombosis research, 2021, Volume: 204 Topics: Anticoagulants; Dabigatran; Female; Humans; Incidence; Pyrazoles; Pyridones; Rivaroxaban; Uterine Hemorrhage; Venous Thromboembolism	2021
Nonvitamin K Antagonist Oral Anticoagulant in Patients With Venous Thromboembolism and Polycythemia Vera or Essential Thrombocythemia: A Cohort Study. Journal of cardiovascular pharmacology, 2021, 11-01, Volume: 78, Issue:5 Topics: Administration, Oral; Aged; Antithrombins; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Polycythemia Vera; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Thrombocythemia, Essential; Time Factors; Treatment Outcome; Venous Thromboembolism	2021
Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study. Journal of thrombosis and thrombolysis, 2022, Volume: 53, Issue:2 Topics: Anticoagulants; Dabigatran; Humans; Pulmonary Embolism; Venous Thromboembolism; Warfarin	2022
Antithrombotic Therapy for Venous Thromboembolic Disease. JAMA, 2017, 05-16, Volume: 317, Issue:19 Topics: Antithrombins; Dabigatran; Humans; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Review Literature as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis; Vitamin K	2017
Extended use of sulodexide, apixaban, rivaroxaban and dabigatran in venous thromboembolism: indirect comparison of clinical trials. International angiology : a journal of the International Union of Angiology, 2017, Volume: 36, Issue:5 Topics: Administration, Oral; Anticoagulants; Dabigatran; Glycosaminoglycans; Hemorrhage; Humans; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Venous Thromboembolism	2017
Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes. Internal and emergency medicine, 2017, Volume: 12, Issue:5 Topics: Administration, Oral; Anticoagulants; Dabigatran; Dose-Response Relationship, Drug; Evidence-Based Medicine; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin	2017
Evaluation of Direct-Acting Oral Anticoagulant Use in Patients With Cancer. Journal of pharmacy practice, 2018, Volume: 31, Issue:5 Topics: Administration, Oral; Aged; Anticoagulants; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Venous Thromboembolism	2018
Measuring Direct Oral Anticoagulants. Methods in molecular biology (Clifton, N.J.), 2017, Volume: 1646 Topics: Administration, Oral; Antithrombins; Blood Coagulation; Dabigatran; Drug Monitoring; Endopeptidases; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thrombin Time; Venous Thromboembolism	2017
Anticoagulation prescribing patterns in patients with cancer. Journal of thrombosis and thrombolysis, 2018, Volume: 45, Issue:1 Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Hemorrhage; Humans; Middle Aged; Neoplasms; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thrombosis; Treatment Outcome; Venous Thromboembolism; Warfarin	2018
Initiation of direct oral anticoagulants versus warfarin for venous thromboembolism: impact on time to hospital discharge. Journal of thrombosis and thrombolysis, 2018, Volume: 45, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Patient Readmission; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Venous Thromboembolism; Warfarin	2018
Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. Thrombosis and haemostasis, 2017, Volume: 117, Issue:11 Topics: Acute Disease; Adult; Age Factors; Aged; Aging; Anticoagulants; Antithrombins; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Kidney; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Risk Factors; Time Factors; Treatment Outcome; Venous Thromboembolism; Warfarin	2017
Measuring Dabigatran Levels: What Tests Are Available and What Still Needs to Be Done? Thrombosis and haemostasis, 2017, Volume: 117, Issue:12 Topics: Animals; Antithrombins; Blood Coagulation Tests; Chromatography, Liquid; Dabigatran; Hemorrhage; Humans; Mass Spectrometry; Sensitivity and Specificity; Venous Thromboembolism	2017
[Angiology and haemostasis. Highlights on some new data in 2017]. Revue medicale suisse, 2018, Jan-10, Volume: 14, Issue:588-589 Topics: Administration, Oral; Anticoagulants; Dabigatran; Hemorrhage; Hemostasis; Humans; Venous Thromboembolism	2018
Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood advances, 2018, 02-13, Volume: 2, Issue:3 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Databases, Factual; Hemorrhage; Humans; Middle Aged; Neoplasms; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Venous Thromboembolism; Warfarin; Young Adult	2018
Dual anticoagulation with fondaparinux and dabigatran for treatment of cancer-associated hypercoagulability. American journal of hematology, 2018, Volume: 93, Issue:6 Topics: Adult; Anticoagulants; Antithrombins; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Fondaparinux; Humans; Lung Neoplasms; Male; Recurrence; Thrombophilia; Thrombosis; Venous Thromboembolism	2018
Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada. Vascular health and risk management, 2018, Volume: 14 Topics: Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dabigatran; Enoxaparin; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Patient Discharge; Pulmonary Embolism; Quebec; Registries; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis	2018
Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism. Journal of thrombosis and haemostasis : JTH, 2018, Volume: 16, Issue:9 Topics: Adolescent; Adult; Anticoagulants; Clinical Trials as Topic; Contraceptives, Oral, Hormonal; Dabigatran; Factor Xa Inhibitors; Female; Humans; Incidence; Menorrhagia; Middle Aged; Multicenter Studies as Topic; Uterine Hemorrhage; Venous Thromboembolism; Vitamin K; Warfarin; Young Adult	2018
Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty. The Journal of arthroplasty, 2018, Volume: 33, Issue:11 Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Conflict of Interest; Dabigatran; Enoxaparin; Female; Fondaparinux; Health Care Sector; Hemorrhage; Humans; Male; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism; Warfarin	2018
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. Journal of thrombosis and haemostasis : JTH, 2018, Volume: 16, Issue:9 Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Factor Xa Inhibitors; Hemorrhage; Humans; Multicenter Studies as Topic; Neoplasms; Observational Studies as Topic; Patient Acceptance of Health Care; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis	2018
All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism. Thrombosis and haemostasis, 2018, Volume: 118, Issue:9 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Risk; Rivaroxaban; Survival Analysis; Thiazoles; Venous Thromboembolism; Warfarin	2018
Dabigatran (Pradaxa) Is Safe for Extended Venous Thromboembolism Prophylaxis After Surgery for Pancreatic Cancer. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2019, Volume: 23, Issue:6 Topics: Administration, Oral; Aged; Antithrombins; Dabigatran; Female; Humans; Male; Pancreatectomy; Pancreatic Neoplasms; Postoperative Complications; Treatment Outcome; Venous Thromboembolism	2019
Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients. Current medical research and opinion, 2019, Volume: 35, Issue:5 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism	2019
Lakartidningen, 2018, 12-04, Volume: 115 Topics: Anticoagulants; Antithrombins; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Neoplasms; Perioperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis	2018
Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding. Circulation, 2019, 02-05, Volume: 139, Issue:6 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Anticoagulants; Dabigatran; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Risk Assessment; United States; Venous Thromboembolism; Vitamin K	2019
The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants. Clinical chemistry and laboratory medicine, 2019, 08-27, Volume: 57, Issue:9 Topics: Administration, Oral; Adult; Anticoagulants; Antiphospholipid Syndrome; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Factor Xa Inhibitors; False Positive Reactions; Female; Humans; Lupus Coagulation Inhibitor; Male; Middle Aged; Partial Thromboplastin Time; Plasma; Prothrombin Time; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism	2019
The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice. Journal of thrombosis and haemostasis : JTH, 2019, Volume: 17, Issue:6 Topics: Animals; Anticoagulants; Antithrombins; Breast Neoplasms; Cell Line, Tumor; Dabigatran; Disease Progression; Factor Xa Inhibitors; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Rivaroxaban; Triple Negative Breast Neoplasms; Venous Thromboembolism; Xenograft Model Antitumor Assays	2019
Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study. Vascular pharmacology, 2019, Volume: 120 Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Comparative Effectiveness Research; Dabigatran; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Pilot Projects; Prospective Studies; Pyrazoles; Pyridones; Recurrence; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome; Venous Thromboembolism; Vitamin K	2019
Get off my back! Inferior vena cava filter erosion into the lumbar spine. BMJ case reports, 2019, Jun-06, Volume: 12, Issue:6 Topics: Aged, 80 and over; Antithrombins; Dabigatran; Female; Humans; Lower Extremity; Lumbar Vertebrae; Vena Cava Filters; Venous Thromboembolism	2019
Extended treatment of venous thromboembolism. The New England journal of medicine, 2013, Feb-21, Volume: 368, Issue:8 Topics: Benzimidazoles; beta-Alanine; Dabigatran; Female; Fibrinolytic Agents; Humans; Male; Pyrazoles; Pyridones; Venous Thromboembolism; Warfarin	2013
Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients. Thrombosis research, 2013, Volume: 131 Suppl 1 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism	2013
DRESS syndrome induced by acenocoumarol with tolerance to warfarin and dabigatran: a case report. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2013, Volume: 24, Issue:5 Topics: Acenocoumarol; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Eruptions; Eosinophilia; Exanthema; Humans; Male; Venous Thromboembolism; Warfarin	2013
[New oral anticoagulants in the treatment of venous thromboembolic disease]. Semergen, 2013, Volume: 39, Issue:3 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism	2013
Venous thromboembolism: prophylactic and therapeutic practice guideline. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2013, Feb-15, Volume: 103, Issue:4 Pt 2 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Chemoprevention; Dabigatran; Disease Management; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Monitoring; Drug Substitution; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Morpholines; Preoperative Care; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Thiophenes; Time Factors; Vena Cava Filters; Venous Thromboembolism	2013
Conventional and new oral anticoagulants in the treatment of chest disease and its complications. American journal of respiratory and critical care medicine, 2013, Aug-15, Volume: 188, Issue:4 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Practice Guidelines as Topic; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K	2013
[Venous thromboembolism. Currently it is worthwhile to use anticoagulants longer]. MMW Fortschritte der Medizin, 2013, Apr-04, Volume: 155, Issue:6 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Long-Term Care; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thromboembolism	2013
[New oral anticoagulant agents: the quandary of anticoagulation in the elderly]. Medicina clinica, 2013, Oct-19, Volume: 141, Issue:8 Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2013
New oral anticoagulants: their role and future. Clinical medicine (London, England), 2013, Volume: 13 Suppl 6 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin	2013
Direct oral anticoagulants for acute venous thromboembolism: closing the circle? Circulation, 2014, Feb-18, Volume: 129, Issue:7 Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Venous Thromboembolism; Warfarin	2014
Thromboprophylaxis with dabigatran leads to an increased incidence of wound leakage and an increased length of stay after total joint replacement. The bone & joint journal, 2014, Volume: 96-B, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy, Combination; Female; Heparin, Low-Molecular-Weight; Humans; Length of Stay; Male; Medical Audit; Middle Aged; Postoperative Care; Postoperative Hemorrhage; Prospective Studies; Venous Thromboembolism	2014
Hip arthroplasty fatality related to dabigatran induced gastrointestinal haemorrhage. Annals of the Royal College of Surgeons of England, 2014, Volume: 96, Issue:1 Topics: Aged; Antithrombins; Arthroplasty, Replacement, Hip; Benzimidazoles; Dabigatran; Fatal Outcome; Female; Gastrointestinal Hemorrhage; Humans; Pyridines; Venous Thromboembolism	2014
New oral anticoagulants for acute venous thromboembolism. The Medical letter on drugs and therapeutics, 2014, Jan-06, Volume: 56, Issue:1433 Topics: Acute Disease; Anticoagulants; Benzimidazoles; Dabigatran; Drug Approval; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism	2014
Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain. PharmacoEconomics, 2014, Volume: 32, Issue:9 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Dabigatran; Decision Trees; Economics, Pharmaceutical; Enoxaparin; Models, Economic; Pyrazoles; Pyridones; Rivaroxaban; Spain; Treatment Outcome; Venous Thromboembolism	2014
New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. American journal of hematology, 2014, Volume: 89, Issue:10 Topics: Administration, Oral; Adult; Anticoagulants; Antiphospholipid Syndrome; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism	2014
Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients. Journal of medical economics, 2014, Volume: 17, Issue:11 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fees, Pharmaceutical; Health Expenditures; Hemorrhage; Humans; Models, Econometric; Monte Carlo Method; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism	2014
Dabigatran: patient management in specific clinical settings. Wiener klinische Wochenschrift, 2014, Volume: 126, Issue:17-18 Topics: Antithrombins; Arthroplasty, Replacement; Austria; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Practice Guidelines as Topic; Venous Thromboembolism	2014
New oral anticoagulants in the management of venous thromboembolism: a major advance? European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2014, Volume: 48, Issue:5 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism	2014
Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial. BMC family practice, 2014, Oct-25, Volume: 15 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Family Practice; Female; Germany; Guideline Adherence; Heart Diseases; Heart Valve Prosthesis; Humans; International Normalized Ratio; Male; Mass Screening; Middle Aged; Morpholines; Practice Guidelines as Topic; Process Assessment, Health Care; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Thrombosis; Venous Thromboembolism	2014
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions. Canadian family physician Medecin de famille canadien, 2014, Volume: 60, Issue:11 Topics: Acute Disease; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Family Practice; Hemorrhage; Humans; Morpholines; Preoperative Care; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Time Factors; Venous Thromboembolism	2014
[Advantages and disadvantages of warfarin and pradaxa therapy for venous thromboembolism]. Vestnik khirurgii imeni I. I. Grekova, 2014, Volume: 173, Issue:4 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Monitoring; Drug Substitution; Female; Hemorrhage; Heparin; Humans; Lower Extremity; Male; Middle Aged; Severity of Illness Index; Tomography, Spiral Computed; Treatment Outcome; Ultrasonography, Doppler, Duplex; Venous Thromboembolism; Warfarin	2014
Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. Journal of medical economics, 2015, Volume: 18, Issue:6 Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Costs and Cost Analysis; Dabigatran; Health Expenditures; Hemorrhage; Humans; Models, Econometric; Myocardial Infarction; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; United States; Venous Thromboembolism; Warfarin	2015
Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thrombosis and haemostasis, 2015, Volume: 114, Issue:1 Topics: Adult; Aged; Anticoagulants; Antithrombins; Dabigatran; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Odds Ratio; Proportional Hazards Models; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Venous Thromboembolism; Warfarin	2015
Dabigatran etexilate and LMWH for the prevention of venous thromboembolism in 532 patients undergoing hip surgery. European review for medical and pharmacological sciences, 2015, Volume: 19, Issue:5 Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weight; Humans; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Pyridines; Venous Thromboembolism	2015
Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer. Internal and emergency medicine, 2015, Volume: 10, Issue:6 Topics: Anticoagulants; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Treatment Outcome; Venous Thromboembolism	2015
Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants. Archives of pathology & laboratory medicine, 2015, Volume: 139, Issue:5 Topics: Adolescent; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Thrombelastography; Venous Thromboembolism; Young Adult	2015
[Importance of appropiate clinical management of direct oral anticoagulants]. Medicina clinica, 2016, Jan-01, Volume: 146, Issue:1 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Drug Monitoring; Hemorrhage; Humans; Retrospective Studies; Rivaroxaban; Spain; Venous Thromboembolism	2016
Attending Physician Attitudes Toward Choice of Oral Anticoagulant for the Treatment of Venous Thromboembolism. Rhode Island medical journal (2013), 2015, Jul-01, Volume: 98, Issue:7 Topics: Administration, Oral; Anticoagulants; Cardiology; Cost-Benefit Analysis; Cross-Sectional Studies; Dabigatran; Health Care Surveys; Hematology; Humans; Internal Medicine; Practice Patterns, Physicians'; Primary Health Care; Rhode Island; Rivaroxaban; Specialization; Venous Thromboembolism; Warfarin	2015
National Trends in Ambulatory Oral Anticoagulant Use. The American journal of medicine, 2015, Volume: 128, Issue:12 Topics: Administration, Oral; Adult; Age Factors; Aged; Ambulatory Care; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Rivaroxaban; United States; Venous Thromboembolism; Warfarin; Young Adult	2015
Extreme warfarin hypersensitivity after oophorectomy. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2015, Volume: 26, Issue:8 Topics: Anticoagulants; Blood Coagulation Factors; Dabigatran; Drug Hypersensitivity; Drug Substitution; Female; Heparin; Humans; International Normalized Ratio; Middle Aged; Ovariectomy; Venous Thromboembolism; Vitamin K; Warfarin	2015
The evolving role of dabigatran etexilate in clinical practice. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:13 Topics: Antithrombins; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Dabigatran; Enoxaparin; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism	2015
The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK. Thrombosis and haemostasis, 2015, Volume: 114, Issue:4 Topics: Acute Disease; Anticoagulants; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Drug Costs; Hemorrhage; Humans; Kaplan-Meier Estimate; Models, Economic; Pulmonary Embolism; Quality-Adjusted Life Years; State Medicine; Time Factors; Treatment Outcome; United Kingdom; Venous Thromboembolism; Venous Thrombosis; Warfarin	2015
Opportunities for improvement: anticoagulation in patients undergoing total knee or hip replacement. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2015, Volume: 20, Issue:6 Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dabigatran; Denmark; Female; Follow-Up Studies; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Postoperative Complications; Quality Improvement; Registries; Retrospective Studies; Risk Assessment; Rivaroxaban; Statistics, Nonparametric; Survival Rate; Treatment Outcome; Venous Thromboembolism	2015
Improving evidence on anticoagulant therapies for venous thromboembolism in children: key challenges and opportunities. Blood, 2015, Dec-10, Volume: 126, Issue:24 Topics: Adult; Age Factors; Anticoagulants; Child; Child, Preschool; Clinical Trials as Topic; Dabigatran; Disease Management; Evidence-Based Medicine; Heparin, Low-Molecular-Weight; Humans; Infant; Multicenter Studies as Topic; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism	2015
Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism. Journal of thrombosis and haemostasis : JTH, 2016, Volume: 14, Issue:1 Topics: Animals; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Disease Models, Animal; Disease Progression; Embolization, Therapeutic; Female; Femoral Vein; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Lung; Mice; Mice, Inbred C57BL; Microscopy, Video; Pulmonary Embolism; Thrombosis; Venous Thromboembolism; Venous Thrombosis	2016
[INFECTIOUS ENDOCARDITIS IN PREGNANT WOMEN]. Klinicheskaia meditsina, 2015, Volume: 93, Issue:7 Topics: Adult; Anti-Bacterial Agents; Antithrombins; Dabigatran; Daptomycin; Echocardiography; Endocarditis, Bacterial; Female; Humans; Methicillin-Resistant Staphylococcus aureus; Mitral Valve; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Tomography, X-Ray Computed; Treatment Outcome; Venous Thromboembolism	2015
ISTH 2015 Congress. The Lancet. Haematology, 2015, Volume: 2, Issue:8 Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Arthroscopy; Blood Loss, Surgical; Dabigatran; Factor VIII; Hemophilia A; Humans; Randomized Controlled Trials as Topic; Rivaroxaban; Single-Domain Antibodies; Venous Thromboembolism	2015
Management of bleeding complications in patients with cancer on DOACs. Thrombosis research, 2016, Volume: 140 Suppl 1 Topics: Anticoagulants; Dabigatran; Hemorrhage; Humans; Neoplasms; Venous Thromboembolism; Vitamin K; Warfarin	2016
Anti-coagulant therapy with dabigatran for cystic fibrosis patients. Pediatric pulmonology, 2016, Volume: 51, Issue:8 Topics: Administration, Oral; Adolescent; Antithrombins; Cystic Fibrosis; Dabigatran; Drug Administration Schedule; Female; Humans; Venous Thromboembolism	2016
Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. The American journal of medicine, 2016, Volume: 129, Issue:11 Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Comorbidity; Creatinine; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Renal Insufficiency; Retrospective Studies; Rivaroxaban; Stroke; Venous Thromboembolism	2016
Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism. Internal and emergency medicine, 2016, Volume: 11, Issue:7 Topics: Administration, Oral; Anticoagulants; Aspirin; Dabigatran; Humans; Italy; Pyrazoles; Pyridones; Rivaroxaban; Time Factors; Venous Thromboembolism; Vitamin K; Warfarin	2016
A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand. Journal of thrombosis and thrombolysis, 2017, Volume: 43, Issue:2 Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Dabigatran; Decision Trees; Enoxaparin; Health Care Costs; Humans; Monte Carlo Method; Postoperative Complications; Premedication; Quality-Adjusted Life Years; Thailand; Venous Thromboembolism	2017
Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands. PloS one, 2016, Volume: 11, Issue:10 Topics: Antithrombins; Cost-Benefit Analysis; Dabigatran; Humans; Models, Theoretical; Netherlands; Probability; Venous Thromboembolism	2016
Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention. Journal of the American Heart Association, 2016, 10-17, Volume: 5, Issue:10 Topics: Aged; Aged, 80 and over; Angina Pectoris; Anticoagulants; Atrial Fibrillation; Comorbidity; Dabigatran; Databases, Factual; Female; Hospital Mortality; Humans; Kaplan-Meier Estimate; Length of Stay; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Patient Readmission; Percutaneous Coronary Intervention; Postoperative Hemorrhage; Propensity Score; Proportional Hazards Models; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stents; Stroke; Thrombosis; Venous Thromboembolism; Warfarin	2016
Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™. Vascular medicine (London, England), 2016, Volume: 21, Issue:6 Topics: Acute Disease; Adult; Aged; Anticoagulants; Antithrombins; Dabigatran; Female; Fibrinolytic Agents; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Factors; Thrombophilia; Time Factors; Treatment Outcome; Venous Thromboembolism; Warfarin	2016
RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. Thrombosis and haemostasis, 2017, 01-26, Volume: 117, Issue:2 Topics: Acute Disease; Anticoagulants; Antithrombins; Blood Coagulation; Cross-Sectional Studies; Dabigatran; Hemorrhage; Humans; Prospective Studies; Pulmonary Embolism; Research Design; Risk Factors; Time Factors; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis; Vitamin K	2017
Non-vitamin K antagonist oral anticoagulants in patients with severe inherited thrombophilia: a series of 33 patients. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2017, Volume: 28, Issue:6 Topics: Adult; Anticoagulants; Dabigatran; Female; Humans; Male; Medication Adherence; Middle Aged; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thrombophilia; Venous Thromboembolism; Young Adult	2017
Italian intersociety consensus on DOAC use in internal medicine. Internal and emergency medicine, 2017, Volume: 12, Issue:3 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Competence; Consensus; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Factor Xa Inhibitors; Food-Drug Interactions; Humans; Internal Medicine; Italy; Liver Diseases; Perioperative Period; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Time Factors; Venous Thromboembolism	2017
Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER Journal of thrombosis and thrombolysis, 2017, Volume: 43, Issue:4 Topics: Adult; Aged; Clinical Trials as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Pulmonary Embolism; Stroke; Venous Thromboembolism; Venous Thrombosis; Warfarin	2017
Thrombotic and bleeding outcomes following perioperative interruption of direct oral anticoagulants in patients with venous thromboembolic disease. Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:5 Topics: Administration, Oral; Aged; Antithrombins; Blood Coagulation; Dabigatran; Drug Administration Schedule; Factor Xa Inhibitors; Female; Half-Life; Humans; Male; Middle Aged; Perioperative Care; Postoperative Hemorrhage; Pyrazoles; Pyridones; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Surgical Procedures, Operative; Time Factors; Treatment Outcome; Venous Thromboembolism	2017
Dabigatran etexilate. Nature reviews. Drug discovery, 2008, Volume: 7, Issue:7 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Humans; Pyridines; Venous Thromboembolism	2008
Dabigatran etexilate for prevention of venous thromboembolism. Thrombosis and haemostasis, 2009, Volume: 101, Issue:1 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Enoxaparin; Hemorrhage; Humans; Pyridines; Risk Assessment; Treatment Outcome; Venous Thromboembolism	2009
[Thrombin inhibitor shows stable safety profile in the practice]. MMW Fortschritte der Medizin, 2008, Dec-11, Volume: 150, Issue:51-52 Topics: Administration, Oral; Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Enoxaparin; Humans; Middle Aged; Primary Prevention; Prodrugs; Pyridines; Thrombin; Venous Thromboembolism	2008
In the pipeline: new oral anticoagulants for the prevention of venous thromboembolism. Orthopedics, 2009, Volume: 32, Issue:1 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2009
Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clinical therapeutics, 2009, Volume: 31, Issue:1 Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dabigatran; Decision Trees; Drug Costs; Enoxaparin; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Markov Chains; National Health Programs; Pyridines; United Kingdom; Venous Thromboembolism	2009
[New agents for the prevention of venous thromboembolism]. Der Internist, 2009, Volume: 50, Issue:6 Topics: Benzimidazoles; Dabigatran; Enoxaparin; Fibrinolytic Agents; Humans; Morpholines; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2009
[The new oral anticoagulant in the Netherlands]. Nederlands tijdschrift voor geneeskunde, 2009, Apr-18, Volume: 153, Issue:16 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Dabigatran; Drug Interactions; Elective Surgical Procedures; Humans; Morpholines; Netherlands; Patient Selection; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism	2009
Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty. Archives of orthopaedic and trauma surgery, 2010, Volume: 130, Issue:5 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Dabigatran; Elective Surgical Procedures; Humans; Morpholines; Postoperative Complications; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism	2010
A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting. PharmacoEconomics, 2009, Volume: 27, Issue:10 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Decision Trees; Enoxaparin; Fibrinolytic Agents; Humans; Ireland; Models, Economic; Monte Carlo Method; Morpholines; Pyridines; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; Venous Thromboembolism	2009
Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. Thrombosis and haemostasis, 2010, Volume: 103, Issue:2 Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Enoxaparin; Health Care Costs; Hemorrhage; Humans; Kidney Diseases; Postoperative Complications; Pyridines; United Kingdom; Venous Thromboembolism	2010
[Pregnancy and venous thromboembolism. North-American and European guidelines. American College of Chest Physicians]. Journal des maladies vasculaires, 2009, Volume: 34, Issue:5 Topics: Abnormalities, Drug-Induced; Adult; Anticoagulants; Benzimidazoles; Blood Loss, Surgical; Cesarean Section; Contraindications; Dabigatran; Europe; Evidence-Based Medicine; Female; Fetus; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Infant, Newborn; Morpholines; Polysaccharides; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Hematologic; Puerperal Disorders; Pyridines; Rivaroxaban; Societies, Medical; Thiophenes; Thrombophilia; United States; Uterine Hemorrhage; Venous Thromboembolism; Warfarin	2009
New agents for orthopaedic thromboprophylaxis: caution essential, but time will tell. ANZ journal of surgery, 2009, Volume: 79, Issue:11 Topics: Anticoagulants; Benzimidazoles; Dabigatran; Enoxaparin; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism	2009
Will direct thrombin inhibition change the boundaries of oral anti-coagulation? QJM : monthly journal of the Association of Physicians, 2010, Volume: 103, Issue:6 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Blood Coagulation; Dabigatran; Humans; Pyridines; Thrombin; Venous Thromboembolism	2010
Dabigatran versus warfarin for venous thromboembolism. The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11 Topics: Anticoagulants; Benzimidazoles; Dabigatran; Drug Monitoring; Humans; Pyridines; Venous Thromboembolism; Warfarin	2010
Dabigatran versus warfarin for venous thromboembolism. The New England journal of medicine, 2010, Mar-18, Volume: 362, Issue:11 Topics: Anticoagulants; Benzimidazoles; Dabigatran; Drug Costs; Humans; International Normalized Ratio; Pyridines; Venous Thromboembolism; Warfarin	2010
Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial). Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:6 Topics: Anticoagulants; Benzimidazoles; Dabigatran; Double-Blind Method; Europe; Hemorrhage; Humans; Middle Aged; Multicenter Studies as Topic; North America; Pyridines; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome; Venous Thromboembolism; Warfarin	2010
Dabigatran: ready for prime time? Polskie Archiwum Medycyny Wewnetrznej, 2010, Volume: 120, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Pyridines; Review Literature as Topic; Treatment Outcome; Venous Thromboembolism	2010
Pooled analysis of trials may, in the presence of heterogeneity inadvertently lead to fragile conclusions due to the importance of clinically relevant variables being either hidden or lost when the findings are pooled. Thrombosis research, 2010, Volume: 126, Issue:3 Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Double-Blind Method; Drug Administration Schedule; Elective Surgical Procedures; Enoxaparin; Evidence-Based Medicine; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Subcutaneous; Meta-Analysis as Topic; Pyridines; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Risk Assessment; Risk Factors; Treatment Outcome; Venous Thromboembolism	2010
Dabigatran etexilate. British journal of clinical pharmacology, 2010, Volume: 70, Issue:1 Topics: Anticoagulants; Benzimidazoles; Dabigatran; Humans; Pyridines; Thrombin; Venous Thromboembolism	2010
Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review. PharmacoEconomics, 2010, Volume: 28, Issue:9 Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Enoxaparin; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Models, Economic; Morpholines; Polysaccharides; Postoperative Complications; Pyridines; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2010
Novel anticoagulants: new evidence for emerging drugs and their potential application in major lower limb surgery. Current vascular pharmacology, 2011, Volume: 9, Issue:1 Topics: Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drugs, Investigational; Factor Xa Inhibitors; Humans; Lower Extremity; Morpholines; Orthopedic Procedures; Pyridines; Rivaroxaban; Thiophenes; Thrombin; Venous Thromboembolism	2011
[Medication of the month. Dabigatran etixilate (Pradaxa): an oral anticoagulant acting as a direct selective inhibitor of thrombin]. Revue medicale de Liege, 2010, Volume: 65, Issue:10 Topics: Anticoagulants; Antithrombin Proteins; Arthroplasty, Replacement; Benzimidazoles; Dabigatran; Humans; Pyridines; Venous Thromboembolism	2010
Warfarin or not. The journal of the Royal College of Physicians of Edinburgh, 2010, Volume: 40, Issue:4 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Pulmonary Embolism; Venous Thromboembolism; Warfarin	2010
[Clinical rationale for using dabigatran etexilate in the complex treatment of venous thromboembolism]. Khirurgiia, 2010, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; Combined Modality Therapy; Dabigatran; Drug Monitoring; Female; Humans; Male; Middle Aged; Prothrombin Time; Pyridines; Tomography, X-Ray Computed; Treatment Outcome; Venous Thromboembolism; Young Adult	2010
Factor Xa and thrombin as targets for new oral anticoagulants. Thrombosis research, 2011, Volume: 127 Suppl 2 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K	2011
New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. BMJ (Clinical research ed.), 2011, Jan-18, Volume: 342 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Interactions; Hemorrhage; Humans; Kidney Diseases; Morpholines; Pyridines; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2011
New insights on the role of direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery. Thrombosis and haemostasis, 2011, Volume: 105, Issue:4 Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Postoperative Complications; Randomized Controlled Trials as Topic; Venous Thromboembolism; Venous Thrombosis	2011
An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. Journal of medical economics, 2011, Volume: 14, Issue:2 Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Female; Health Care Costs; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Risk; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism	2011
Place of dabigatran in contemporary pharmacotherapy. Pharmacotherapy, 2011, Volume: 31, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Approval; Humans; Stroke; United States; United States Food and Drug Administration; Venous Thromboembolism	2011
New oral anticoagulants for venous thromboembolism prophylaxis in orthopaedic surgery. Instructional course lectures, 2011, Volume: 60 Topics: Anticoagulants; Antithrombin Proteins; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2011
[New anticoagulants in the prevention and treatment of venous thromboembolism]. Orvosi hetilap, 2011, Jun-19, Volume: 152, Issue:25 Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Costs; Drugs, Investigational; Factor Xa Inhibitors; Humans; Hungary; Morpholines; Oligosaccharides; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism	2011
New anticoagulants: moving on from scientific results to clinical implementation. Annals of medicine, 2011, Volume: 43, Issue:8 Topics: Acute Coronary Syndrome; Anticoagulants; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diet; Drug Interactions; Factor VIIa; Factor Xa Inhibitors; Humans; Kidney; Life Style; Monitoring, Physiologic; Morpholines; Recombinant Proteins; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K	2011
["Xa-tra-xa": opportunities and open questions about new anticoagulants]. Praxis, 2011, Aug-10, Volume: 100, Issue:16 Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2011
Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach. Postgraduate medicine, 2012, Volume: 124, Issue:1 Topics: Aged; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Decision Trees; Drug Costs; Elective Surgical Procedures; Enoxaparin; Female; Humans; Male; Markov Chains; Models, Economic; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; State Medicine; Thiophenes; United Kingdom; Venous Thromboembolism	2012
Oral thromboprophylaxis following total hip replacement: the issue of compliance. Orthopaedics & traumatology, surgery & research : OTSR, 2012, Volume: 98, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Aged; Antithrombin Proteins; Arthroplasty, Replacement, Hip; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Medication Adherence; Middle Aged; Postoperative Complications; Prospective Studies; Pyridines; Treatment Outcome; Ultrasonography, Doppler; Venous Thromboembolism; Young Adult	2012
Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands. Journal of medical economics, 2012, Volume: 15, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzimidazoles; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Female; Fibrinolytic Agents; Humans; Infusions, Subcutaneous; Male; Middle Aged; Netherlands; Orthopedics; Postoperative Complications; Primary Prevention; Pyridines; Retrospective Studies; Venous Thromboembolism	2012
Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting. PharmacoEconomics, 2012, Oct-01, Volume: 30, Issue:10 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Decision Making; Enoxaparin; Guidelines as Topic; Health Care Costs; Humans; Ireland; Models, Economic; Morpholines; Pyridines; Quality-Adjusted Life Years; Rivaroxaban; Technology Assessment, Biomedical; Thiophenes; Time Factors; Venous Thromboembolism	2012
Prescribing trends for dabigatran etexilate in primary care. Irish medical journal, 2012, Volume: 105, Issue:5 Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Ireland; Male; Off-Label Use; Postoperative Complications; Practice Patterns, Physicians'; Primary Health Care; Retrospective Studies; Stroke; Venous Thromboembolism	2012
Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis. Thrombosis research, 2012, Volume: 130, Issue:5 Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Body Mass Index; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Middle Aged; Obesity; Postoperative Complications; Risk Factors; Treatment Outcome; Venous Thromboembolism	2012
Dabigatran emerges as safe and effective warfarin alternative. The recently approved drug is more expensive, but appears to be more predictable. Heart advisor, 2011, Volume: 14, Issue:1 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Interactions; Humans; Stroke; United States; United States Food and Drug Administration; Venous Thromboembolism; Warfarin	2011
Periprocedural anticoagulant management. Hospital practice (1995), 2012, Volume: 40, Issue:3 Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Coronary Restenosis; Dabigatran; Heart Valve Prosthesis; Hemorrhage; Humans; Morpholines; Neoplasms; Perioperative Care; Risk Assessment; Rivaroxaban; Stents; Thiophenes; Venous Thromboembolism; Warfarin	2012
Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clinical chemistry and laboratory medicine, 2012, Volume: 50, Issue:9 Topics: Anticoagulants; Benzimidazoles; Blood Coagulation Tests; Colorimetry; Dabigatran; Factor XIII; Humans; Partial Thromboplastin Time; Prothrombin; Prothrombin Time; Pyridines; Stroke; Venous Thromboembolism	2012
New ESC guidelines on atrial fibrillation accept reality of next generation of anti-coagulants. Cardiovascular journal of Africa, 2012, Volume: 23, Issue:9 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Europe; Humans; Postoperative Complications; Practice Guidelines as Topic; United States; Vascular Surgical Procedures; Venous Thromboembolism; Warfarin	2012
[New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? Yes]. Revista clinica espanola, 2012, Volume: 212 Suppl 1 Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin	2012
[Dabigatran: beyond the RE-LY study]. Revista clinica espanola, 2012, Volume: 212 Suppl 2 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Pyridines; Randomized Controlled Trials as Topic; Stroke; Venous Thromboembolism; Warfarin	2012
[Dabigatran: transforming the management of oral anticoagulation]. Revista clinica espanola, 2012, Volume: 212 Suppl 2 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Pyridines; Randomized Controlled Trials as Topic; Stroke; Venous Thromboembolism	2012
New oral anticoagulants. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2013, Mar-05, Volume: 185, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Canada; Contraindications; Dabigatran; Drug Dosage Calculations; Drug Interactions; Humans; Morpholines; Postoperative Complications; Pyridines; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis	2013
[New anticoagulants: better knowledge, better prescriptions]. Revue medicale suisse, 2012, Jan-18, Volume: 8, Issue:324 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K	2012
Dabigatran vs. low molecular weight heparin in preventing venous thromboembolism after elective hip and knee arthroplasty: evaluation of selected clinical parameters. Polish orthopedics and traumatology, 2012, Oct-25, Volume: 77 Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Postoperative Complications; Pyridines; Randomized Controlled Trials as Topic; Venous Thromboembolism; Venous Thrombosis	2012
[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement]. Revista espanola de salud publica, 2012, Volume: 86, Issue:6 Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Budgets; Cost Control; Dabigatran; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Spain; State Medicine; Thiophenes; Venous Thromboembolism	2012
Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. Journal of thrombosis and thrombolysis, 2013, Volume: 35, Issue:2 Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Orthopedic Procedures; Primary Prevention; Rivaroxaban; Thiophenes; Venous Thromboembolism	2013
Development of oral anticoagulants. British journal of clinical pharmacology, 2007, Volume: 64, Issue:3 Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Drug Delivery Systems; Drug Design; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Postoperative Hemorrhage; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Warfarin	2007
Dabigatran versus enoxaparin after total hip replacement. Lancet (London, England), 2007, Dec-15, Volume: 370, Issue:9604 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Enoxaparin; Humans; Phlebography; Postoperative Complications; Pyridines; Venous Thromboembolism	2007
[Oral anticoagulation after major hip or knee replacement surgery: a process-driven managerial pharmacoeconomic analysis in German hospitals]. Der Orthopade, 2008, Volume: 37, Issue:5 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Economics, Pharmaceutical; Germany; Health Care Costs; Heparin, Low-Molecular-Weight; Humans; Postoperative Complications; Pyridines; Retrospective Studies; Treatment Outcome; Venous Thromboembolism	2008